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Cancers  harbor  signiﬁcant  genetic  heterogeneity  and  patterns  of  relapse  following  many  therapies  are
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signiﬁcant  levels  of toxicity  have  stymied  efforts  to effectively  treat  cancer  with  multi-drug  combinations
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using  currently  approved  therapeutics.  We  discuss  the  relationship  between  tumor-promoting  inﬂam-
mation  and  cancer  as part  of a larger  effort  to develop  a  broad-spectrum  therapeutic  approach  aimed
at  a  wide  range  of  targets  to  address  this  heterogeneity.  Speciﬁcally,  macrophage  migration  inhibitory
factor, cyclooxygenase-2,  transcription  factor  nuclear  factor-B,  tumor  necrosis  factor  alpha,  inducible
nitric oxide  synthase,  protein  kinase  B, and  CXC  chemokines  are  reviewed  as  important  antiinﬂammatory
targets  while  curcumin,  resveratrol,  epigallocatechin  gallate,  genistein,  lycopene,  and  anthocyanins  are
reviewed  as  low-cost,  low  toxicity  means  by which  these  targets  might  all  be  reached  simultaneously.
Future  translational  work  will need  to assess  the  resulting  synergies  of  rationally  designed  antiinﬂam-
matory mixtures  (employing  low-toxicity  constituents),  and  then  combine  this  with  similar  approaches
targeting  the most  important  pathways  across  the  range  of cancer  hallmark  phenotypes.
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. Introduction
In 1863, Rudolf Virchow ﬁrst proposed the role of inﬂam-
ation in cancer, after observing the presence of leukocytes
n neoplastic tissue [1]. Since Virchow’s initial observation that
nﬂammation and cancer are linked, empirical evidence has under-
cored inﬂammation as both a cause and consequence of cancer
2,3]. The inﬂammatory milieu promotes a cellular microenvi-
onment that favors the expansion of genomic aberrations and
he initiation of carcinogenesis [4]. While acute inﬂammation is
redominantly considered to be a self-limiting process and an
mportant component of the immune system with therapeutic sig-
iﬁcance, inadequate or incomplete resolution of inﬂammatory
esponses frequently leads to various chronic diseases, including
ancer [5,6]. In fact, numerous epidemiological and clinical stud-
es have indicated that chronic unresolved inﬂammation promotes
nd exacerbates malignancy [7]. Several types of cancer arise in the
etting of chronic inﬂammation suggesting a strong link between
nﬂammation and cancer [3,8].
It has been estimated that about 25% of all cancers are etiologi-
ally linked to chronic inﬂammation and infection [9]. For example,
he risk of colorectal cancer has been found to be 10-fold higher in
nﬂammatory bowel disease, such as ulcerative colitis and Crohn’s
isease [10]. The risk for cancer of the respiratory system is pos-
tively associated with the severity and duration of inﬂammatory
iseases [11]. Possible associations have also been found between
nﬂammatory diseases, such as esophagitis and Barrett’s metapla-
ia, and esophageal cancer [12] and between chronic pancreatitis
nd pancreatic cancer [13]. Emerging studies have established a
rucial role of chronic, unresolved inﬂammation in the promotion
nd progression of breast cancer, including the most aggressive
ype known as inﬂammatory breast cancer [14,15]. The ovarian
pithelial inﬂammation is linked to ovarian cancer [16]. Likewise,
oreskin inﬂammation (phimosis) has been associated with penile
ancer [17]. Helicobacter pylori (H. pylori) infection and associated
nﬂammation in the gastrointestinal tract represent the leading
ause of adenocarcinoma [12]. Hepatic inﬂammation, due to expo-
ure to infectious agents including hepatitis B virus and hepatitis
 virus as well as toxic compounds, represent an early step in the
evelopment of hepatocellular carcinoma [18]. Moreover, chronic
rostatitis, due to persistent bacterial infection or noninfective
timuli, has been linked to prostate cancer [19]. All of this evidence
upports an association between chronic inﬂammation and cancer
evelopment.
Chronic inﬂammation is linked to various phases implicated
n tumorigenesis, such as cellular proliferation, transformation,
poptosis evasion, survival, invasion, angiogenesis and metasta-
is [7,8,20]. A number of proinﬂammatory molecules within the
umor microenvironment participate in a complex signaling net-
ork that enables extravasations of tumor cells through the stroma,
esulting in promotion of tumor progression [21]. Inﬂammation
s known to contribute to the process of carcinogenesis medi-
ted through the generation of reactive oxygen species (ROS) and Ltd.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
reactive nitrogen species (RNS) capable of damaging the DNA at the
site of the tumor [22]. Free radicals and aldehydes, produced dur-
ing chronic inﬂammation, can induce deleterious gene mutation
and post-translational modiﬁcations of key cancer-related proteins
[23]. Damage can also occur in tissues that are distant from the
tumor [24].
Other procarcinogenic products of inﬂammation include
cytokines, such as tumor necrosis factor- (TNF-), interleukin-
1 (IL-1) and interleukin-6 (IL-6), as well as chemokines,
prostaglandins, oncogenes, inducible nitric oxide synthase (iNOS),
cyclooxygenase-2 (COX-2), 5-lipoxygenase, matrix metallopro-
teinases (MMPs), vascular endothelial growth factor (VEGF),
hypoxia-inducible factor-1 (HIF-1), nuclear factor-B (NF-B),
nuclear factor of activated T-cells, signal transducers and acti-
vators of transcription 3 (STAT3), activator protein-1 (AP-1),
cAMP response binding protein/p300 (CBP/p300), and CCAAT
enhancer binding protein (C/EBP) [25–28]. Additionally, activation
of various upstream kinases, including IB kinase (IKK), protein
kinase C (PKC), mitogen-activated protein kinase (MAPK), and
phosphoinositide-3 kinase/protein kinase B (PI3K)/AKT, are known
to participate in inﬂammation-driven oncogenesis [28]. The pro-
cancerous outcome of chronic inﬂammation is increased DNA
damage, increased DNA synthesis, cellular proliferation, the dis-
ruption of DNA repair pathways and cellular milieu, the inhibition
of apoptosis, the promotion of angiogenesis and invasion.
As well, chronic inﬂammation has an inﬂuence on immune sys-
tem constituents that are directly linked with cancer progression.
Under normal conditions, immune cells, including macrophages,
granulocytes, mast cells, dendritic cells (DCs), innate lymphocytes,
and natural killer (NK) cells serve as the front line of defense
against pathogens. When tissue disruption occurs, macrophages
and mast cells secrete matrix-remodeling proteins, cytokines
and chemokines, which activate local stromal cells (ﬁbroblasts,
adipocytes, vascular cells and others) to recruit circulating leuko-
cytes into damaged tissue (acute inﬂammation), to eliminate the
pathogens [29]. However, when these processes are initiated in
the tumor microenvironment, they are not resolved which leads to
chronic inﬂammation of the “damaged” (tumor) tissue. Thus, while
acute inﬂammation normally supports and balances two opposing
needs for the repair of damaged tissues (apoptosis and wound heal-
ing), chronic inﬂammation represents a loss of this balance and the
resulting conﬂuence of factors has deleterious implications for the
immune system [30].
For example, chronic inﬂammation is directly associated with
immunosuppression mediated primarily by immature myeloid-
derived suppressor cells (MDSCs) [31]. Several factors induce MDSC
differentiation arrest thus suppressing the host’s innate and adap-
tive immune systems, which are essential for effective antitumor
responses [31]. For example, chronically activated leukocytes sup-
ply mitogenic growth factors that stimulate proliferation of cancer
and stromal cells [29,32]. Similarly, cluster of differentiation (CD)4+
T helper cells (e.g., subsets TH1, 2, 9, 10, 17, and 22) are key regula-
tors of inﬂammation in cancer, and these cells secrete cytokines
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hich are needed in immune responses [33] and contribute to
umorigenesis in a variety of ways, depending on context [29].
ndeed, the many effects that these chronically activated immune
ystem constituents have on neoplastic progression have been the
ubject of intense interest by cancer researchers [3,34,35].
Our intent here is not to elaborate on these details, but rather to
iscuss the relationship between tumor-promoting inﬂammation
nd cancer as part of a larger effort to develop a broad-spectrum
herapeutic approach aimed at a wide range of therapeutic tar-
ets relevant for cancer biology. A nonproﬁt organization, entitled
etting to Know Cancer launched an initiative called “The Halifax
roject” in 2011 with the aim of producing a series of overarch-
ng reviews in each of the areas that are widely considered to be
ancer hallmarks [36]. The basis of this novel approach is premised
n many of the insights of genomic sequencing in cancers. Can-
ers harbor signiﬁcant genetic heterogeneity [37], and patterns of
elapse following many therapies are due to evolved resistance
o treatment. While efforts have been made to combine targeted
herapies, a lack of success, rising drug costs and signiﬁcant lev-
ls of toxicity have stymied efforts to effectively treat cancer with
ulti-drug combinations using currently approved therapeutics
38]. Consequently, this approach aims to target many disease-
peciﬁc pathways simultaneously – using low-cost chemistry with
ittle to no toxicity – to address this heterogeneity (in contrast to the
imited number of actionable targets that have become the norm
n combination chemotherapy).
To accomplish this task, the concept of the hallmarks of can-
er [36] was used as a broad organizing framework and tumor –
romoting inﬂammation was one of the areas of focus. We were
peciﬁcally tasked to assess the many target choices that exist
or inﬂammation related to cancer, and identify up to ten impor-
ant targets as well as prospective non-toxic approaches that could
otentially be combined to produce a low-toxicity approach to the
uppression of tumor-promoting inﬂammation. In theory, inclusive
nvestigation toward inﬂammatory associated carcinogenic path-
ays and associated therapeutics would also be combined with
imilar approaches being recommended for the other hallmark
reas under review in this special issue. To that end, a list of seven
mportant therapeutic targets was identiﬁed by this team along
ith seven corresponding approaches (i.e., approaches that have
een shown to have potential to reach those targets) to support
his objective. In addition to looking at the traditional pathways
ssociated with the chosen approaches, we also review the known
mpact of these approaches on microRNA, a relatively new area of
ntense interest in cancer research. The following is a description
f those targets and approaches.
. Therapeutic targets
The following therapeutic targets are reviewed in relation to
nﬂammation: macrophage migration inhibitory factor (MIF), COX-
, NF-B, tumor necrosis factor alpha (TNF-),  iNOS, AKT and CXC
hemokines.
.1. Macrophage migration inhibitory factor (MIF)
The hypothalamic–pituitary–adrenal (HPA) axis (also known
s the stress-axis) sits at the apex of the human inﬂammatory
esponse. Daily ﬂuctuations of bodily inﬂammation are managed
nd regulated in a diurnal pattern [39] by the release of cortisol
rom the adrenal gland. The hypothalamus is comprised of a diverse
roup of nuclei at the base of the brain which integrates infor-
ation from a range of stimuli (e.g., circulating hormone levels in
he blood) and generates appropriate responses based on ambi-
nt conditions. In the HPA-axis, the secretory neurons within the
ypothalamus secrete corticotrophin-releasing hormone (CRH),r Biology 35 (2015) S151–S184 S153
which in turn stimulates the secretion of adrenocorticotropic
hormone (ACTH) from the pituitary gland, which subsequently acts
on the adrenal cortex to promote cortisol release [40]. A nega-
tive feedback loop completes the HPA circuit resulting in cortisol
suppressing the production of CRH and ACTH through feedback
to both the hypothalamus and pituitary [40]. The stress-axis is
therefore widely recognized for its role in the stress response, but
adrenal cortisol is also a vitally important steroid hormone that
plays a critical role in the ongoing modulation of the inﬂammatory
and immune responses. Speciﬁcally, cortisol achieves this media-
tion of the inﬂammatory cascade, in part, by acting on the master
immune/inﬂammatory cytokine MIF.
MIF  is released from macrophages and T lymphocytes that have
been stimulated by glucocorticoids, and is a potent proinﬂam-
matory cytokine that binds to the CD74 molecule on immune
cells in an acute immune response, which provides the coupling
between the HPA-axis and inﬂammation [41,42]. In general, the
HPA-axis is able to regulate inﬂammation with low concentrations
of cortisol which induce MIF  [41], and higher levels of cortisol which
result in decreases in MIF  secretions [42]. As proinﬂammatory
cytokine, MIF  overcomes the inhibitory effects of glucocorticoids
on TNF-, IL-1, IL-6, and IL-8 production [43].
In cancer, MIF  is frequently elevated [44] and it has been
widely implicated in tumor growth and progression. Speciﬁcally,
the effects of MIF  extends to multiple processes fundamental to
tumorigenesis such as proliferation, tumor suppressor downreg-
ulation, evasion of apoptosis, angiogenesis, and tissue invasion
[45,46]. MIF  signaling is involved in COX-2 and PGE2 upregula-
tion, the activation of the extracellular-signal-regulated kinases
(ERK)-1/2 and AKT pathways, and the regulation of c-Jun activation
domain-binding protein-1 (JAB1), p53, Skp1–Cul1–F-box-protein
(SCF) ubiquitin ligases and HIF-1, which are central to growth
regulation, apoptosis and cell cycle control [45,47,48]. MIF  also
upregulates TNF- [49] which is believed to occur via an ampli-
fying proinﬂammatory loop [50]. In chronic lymphocytic leukemia
(CLL) cells, the binding of MIF  to CD74 induces NF-B activation
[51]. MIF  contributes to the immune escape of malignant gliomas
by counteracting NK and cytotoxic T-cell-mediated tumor immune
surveillance [52].
Anti-MIF therapeutics are therefore believed to have consid-
erable promise for many types of cancer [53–57]. Indeed several
MIF-inactivating strategies have proven successful in delaying can-
cer growth, including ISO-66, a synthetic MIF  inhibitor which
caused a signiﬁcant decrease in tumor burden when administered
to mice with established syngeneic melanoma or colon cancer [58].
Recently human anti-MIF antibodies have been tested for their abil-
ity to inﬂuence growth rate and invasion of the human PC3 prostate
cancer cell line in vitro, and in a PC3-xenograft mouse model in vivo.
Treatment with human anti-MIF antibodies suppressed xenograft
tumor growth in a dose-dependent manner [53].
However, it should be noted that MIF  may also be crucial for
controlling infection. In a Ugandan cohort, genetic low expressers of
MIF  were 2.4-times more frequently identiﬁed among patients with
Mycobacterium tuberculosis (TB) bacteremia compared to those
without. MIF-deﬁcient mice have been shown to succumb to infec-
tion more quickly (with higher organism burden and decreased
innate cytokine production) and MIF-deﬁcient macrophages show
a decrease in cytokine production and impaired mycobacterial
killing. So MIF  is a crucial upstream mediator in the innate immune
response to mycobacteria [59], and an increased risk of infection
could be a concern in any therapeutic approach aimed at suppress-
ing MIF.2.2. COX-2
The arachidonic acid (AA) cascade (see Fig. 1) plays a vital
role in mediating either the suppression or induction of the
S154 A.K. Samadi et al. / Seminars in Cancer Biology 35 (2015) S151–S184
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nﬂammatory response [60]. COX-1 and COX-2 are the primary
egulatory enzymes responsible for the translation of AA into the
everal prostanoids, lipid mediators involved in many biological
unctions [61]. While COX-1 is a constitutive enzyme responsible
or several house-keeping functions, the inducible form, COX-2,
s responsible for various inﬂammatory events. COX-2 is readily
vailable to perform both oxygenation and reduction of AA [62].
OX-1/COX-2, also known as prostaglandin (PG) H synthase, trans-
orms AA into PGG2, which is then reduced further by PGH synthase
o form PGH2 [61]. PGH2 then further metabolizes via PG syn-
hases into PGE2, PGD2, PGI2, PGF2, and TXA2, which are then
aired with distinctive G protein-coupled receptors [61,63]. The
roinﬂammatory messenger prostaglandin E2 (PGE2) has further
een linked to carcinogenesis [64]. PGE2 is an agonist toward
rostaglandin E receptors, which are divided into four subtypes,
P1-4 [63,64]. The binding of PGE2 to four PGE receptors along with
eterotrimeric GTP-binding proteins, results in the activation of
denylyl cyclase, stimulated via EP2 and EP4 binding, or phospho-
ipase C, stimulated via EP1 and EP3 binding [65]. This stimulation
f the PGE receptors thus results in the formation of cyclic AMP
cAMP) or the mobilization of intracellular calcium [65]. PGE2 has
oted tumorigenic properties and contributes to carcinogenesis by
romoting insensitivity to antigrowth signals, evasion of apoptosis,
ustained angiogenesis, and tissue invasion/metastasis [61].
Elevated levels of COX-2 have been associated with both car-
inogenesis and cancer progression [66]. Overexpression of COX-2
as been associated with carcinogenesis in animal models, and in
everal human cancers [67–71]. In human UV-induced skin car-
inogenesis, elevation of COX-2 activity is associated with the
ctivation of proinﬂammatory transcription factors (NF-B, AP-
, STAT3 and others) [72]. COX-2 is transcriptionally regulated
nd its promoter is activated by multiple transcription factors, acid cascade.
either alone or in combination [73–75]. This leads to breast, gas-
trointestinal, hematological prostate and oral cancers [68–78].
COX-2 induces carcinogenesis through the aromatase pathway,
particularly in estrogen positive breast cancers, and through the
COX/lipoxygenase (LOX) pathway in estrogen-independent breast
tumors [78]. Recently, elevated activity of COX-2 has been found to
be correlated with chemoresistance through altered redox induced
EGFR-mediated activation of the cell survival cascade (AKT/c-
FLIP/COX-2), which results in diminished drug-induced apoptosis
[79].
The indirect role of the COX-2/PGE2 pathway in regulating
the tumor immune microenvironment has also been suggested
through IL-17 promoting M2 macrophage differentiation [80]. The
interplay between cancer and stroma via COX-2 and indoleamine
2,3-dioxygenase (IDO) promotes tumor progression and predicts
poor patient survival [81]. COX-2 is also known to promote the
development of MDSCs which directly suppress T cell immune
responses. Indeed MDSCs accumulate in the blood, lymphoid
organs, spleens and tumor tissues of cancer patients [82] and serve
as critical mediators of tumor-associated immune suppression [83],
but recently it was  shown that a COX-2 blockade inhibited accu-
mulation and function of MDSCs and restored T-cell response after
traumatic stress [84]. So COX-2 inhibition may  also prove to be an
attractive target for counteracting MDSC-mediated immune sup-
pression in cancer [83]. However, it should be noted that chronic
inhibition of Cox-2 activity or expression, is noted to blunt the
ability of B cells to produce antiviral antibodies, thereby possibly
increasing susceptibility to viral infection [85], which has relevance
for numerous cancers that are virus-related.COX-2 expression and its activity are inhibited by small molecu-
lar inhibitors both synthetic and natural such as NSAIDS, capsaicin
and curcumin [86,87]. Recently, melatonin has also been found to
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nhance the antitumor effect of ﬁsetin by inhibiting COX-2/iNOS
nd NF-B/p300 signaling pathways [88]. However, clinically, the
ost effective way to inhibit COX-2 is with selective pharmacolog-
cal inhibitors, notably rofecoxib, valdecoxib and celecoxib. Several
linical trials of COX-2 inhibitors, including rofecoxib and celecoxib
ere performed and their clinical usage was recommended for pre-
ention of colorectal cancers. These studies showed unequivocally
hat up to 50% reduction in colonic polyps was achieved by daily
se of 800 mg  COX-2 inhibitors in patients with familial adeno-
atous polyposis [89]. However, this is not currently practiced due
o the subsequent ﬁndings of severe cardiovascular risk associated
ith COX-2 inhibitors in a small patient subpopulation (resulting
n the withdrawal of rofecoxib and valdecoxib in 2004 and 2005,
espectively).
The search for more speciﬁc inhibitors of COX-2 for long-term
reventative use has not been very successful, other than the clas-
ic NSAID, aspirin in lower dose. Long-term use of natural COX
nhibitors, such as curcumin and capsaicin has signiﬁcant poten-
ial, at least for the prevention of gastrointestinal tumors [90–93].
he low bioavailability of these natural compounds by oral admin-
stration is a challenge that has limited their use in other solid
umors.
.3. NF-B
NF-B transcription factors are evolutionarily conserved, coor-
inating regulators of immune and inﬂammatory responses that
lay a pivotal role in oncogenesis [94]. NF-B belongs to a class of
ranscription factor family designated as p65 (RelA), RelB, c-Rel, NF-
B1 and NF-B2. NF-B1 and NF-B2 are synthesized as pro-forms,
105 and p100, which are proteolytically processed to active p50
nd p52 respectively [95,96].
All NF-B family members form mono- or heterodimers and
hare common structural features including a Rel homology
omain, which is essential for dimerization and binding to cognate
NA elements [97]. These dimers bind to inhibitory protein IB
amily of proteins (inhibitors of NF-B) preventing their binding to
NA domains and localizing them to the cytoplasm in most quies-
ent cells [98]. Furthermore, the complexity of this transcriptional
egulation system is also ampliﬁed by the fact that different NF-B
imers have differential preferences for variations of the DNA-
inding sequence [99]. Therefore distinct NF-B dimers induce
ifferent target genes. Low frequency shuttling between nucleus
nd cytoplasm is observed which might be the basis for low basal
ranscriptional activity of NF-B and indicative of rapid NF-B/IB
ssociation and re-association events.
NF-B proteins are activated by phosphorylation and polyu-
iquitination of IB and subsequent proteasomal degradation. IB
hosphorylation is catalyzed by an enzyme complex containing IB
inases (IKK1/IKK  and IKK2/IKK) and at least one non-catalytic
ccessory protein (NF-B essential modulator, NEMO, also called
KK) [100,101]. Furthermore, p105 and p100 are cleaved to active
50 and p52 forms respectively by targeted polyubiquitination and
roteasomal degradation [102]. IB and IKK complex bind to other
omponents and interact with other upstream kinases [103]. NF-B
nducing kinase (NIK) phosphorylates and activates IKK1, mitogen-
ctivated protein kinase kinase kinase 1 (MEKK1), MEKK2, MEKK3
nd transforming growth factor beta (TGF-) activating kinase 1
TAK1) [104–106].
NF-B is activated by canonical and non-canonical activation
athways. In the canonical activation pathway, ligands interact
nd activate toll-like receptors (TLRs), the IL-1 receptor (IL-1R),
umor necrosis factor receptor (TNFR) and antigen receptors. TNF-
, lipopolysaccharide (LPS) and IL-1- are typical stimulating
olecules [107,108]. Alternatively, the non-canonical pathway
riginates from different classes of receptors including B-cellr Biology 35 (2015) S151–S184 S155
activation factor, lymphotoxin -receptor (LTR), CD40, receptor
activator for NF-B (RANK), TNFR2 and fn14 [109]. These receptors
stimulate NF-B by activation of the kinase NIK and phosphor-
ylation of IKK1. IKK1 subsequently results in phosphorylation,
ubiquitination and partial degradation of p100 to p50 [110]. There-
fore, the non-canonical activation of NF-B is independent of the
activity of IKK2 and NEMO [111].
Upon activation, NF-B dimers move to the nucleus and their Rel
homology domains are free to bind cognate DNA-sequences in the
enhancer elements of target gene promoters. Thousands of differ-
ent target genes can be transcriptionally activated. Recent reports
point to the role of NF-B in inﬂammation and induction of cancer.
Physical, physiological and/or oxidative stress results in activation
of innate immunological processes leading to inﬂammation which
is associated with canonical activation of the NF-B signaling path-
way [112]. NF-B has a dual effect on inﬂammation. On one hand,
the activation of NF-B, as part of the acute immune response,
activates cytotoxic immune cells against cancer cells [113]. How-
ever, the activation of NF-B also results in up-regulation of
antiapoptotic genes and the induced expression of other proinﬂam-
matory cytokines (e.g., TNF-, IL-1, IL-6, and IL-8) and adhesion
molecules which leads to the recruitment of leukocytes to the
site of inﬂammation [114]. Both, STAT3 and HIF1 pathways are
interconnected with NF-B signaling and interact with NF-B.
For example, the proinﬂammatory cytokine IL-6, encoded by NF-
B target genes, is important for STAT3 activation. STAT3 and
NF-B also co-regulate numerous oncogenic and inﬂammatory
genes [115]. These observations suggest that NF-B and STAT3
alone or in combination induce inﬂammation and an inﬂammatory
microenvironment.
NF-B activation is also involved in growth regulation [116],
and contributes to tumor progression by controlling vasculariza-
tion of tumors via upregulation of VEGF and its receptors [117,118].
The activation of NF-B also causes an increase in the expression
of the transcription factor Snail, which is essential in the TNF--
induction of the epithelial–mesenchymal transition (EMT) [119],
which enables cancer progression and metastasis.
NF-B-induced transcriptional regulation of HIF-1  is mediated
by the recruitment of the NF-B complex to the HIF-1  promoter
[120]. Chronic expression of the proinﬂammatory protein tissue
transglutaminase (TG2) reprograms the transcription regulatory
network in epithelial cells via constitutive activation of NF-B. TG2-
induced NF-B binds the functional NF-B binding site in HIF-1
promoter and results in its increased expression at transcription
and protein levels even under normoxic conditions. Like NF-B,
HIF-1 is also considered a negative prognostic factor because
of its ability to promote chemoresistance, angiogenesis, invasive-
ness, metastasis, resistance to cell death, altered metabolism, and
genomic instability [121]. So aberrant activation of NF-B and its
downstream events (HIF-1,  Snail, Twist, and Zeb expression) can
induce EMT, stem cell-ness, and endow cancer cells with the abil-
ity to disseminate, survive in stressful environments, and regrow
at metastatic sites, making NF-B a very important target.
However, under normal conditions, NF-B plays an important
role in the maintenance of host defense responses so it may  not
be practical to inhibit NF-B on a sustained basis. For example, in
studies on mice, a prolonged inhibition of NF-B activity resulted
in animals that were more susceptible to bacterial infection [122].
So short-term treatment with speciﬁc bioactive inhibitors of IKK
activity might be a preferred means to reduce systemic toxic-
ity and avoid broad suppression of innate immunity. Ideally, an
IKK/NF-B molecular-targeted inhibitor would prevent NF-B acti-
vation without any effects on other signaling pathways, and be
differentially active in tumor cells versus in normal cells. But one
major shortcoming that will need to be addressed before targeted
anti-IKK or NF-B therapies become successful is the surprising
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ut pronounced ability of NF-B activation inhibitors to enhance
he production of IL-1 and related cytokines (due to excessive
nﬂammasome activation) during bacterial infections [123]. So any
trategy that inhibits NF-B will need to be carefully monitored for
mmune-related side-effects.
.4. TNF-˛
TNF- is a key proinﬂammatory cytokine, secreted by inﬂam-
atory cells, which is involved in inﬂammation-associated
arcinogenesis. It was named TNF- because it can induce tumor
egression through the induction of cell death [124]. TNF- is
nvolved in inﬂammation and immunity, but also in a multitude of
iological processes including apoptosis, cell survival, angiogenesis
nd tumor cell migration and invasion [125].
TNF- acts primarily via two receptors TNFR1 and TNFR2
126]. TNF- is a 17 kDa protein consisting of 157 amino acids
hat is a homotrimer in solution, and it is primarily produced in
acrophages, T lymphocytes, and NK cells. However lower expres-
ion levels have been reported in other cells including ﬁbroblasts,
mooth muscle cells, and tumor cells. Although TNF- binds TNFR2
ve times higher than TNFR1, TNFR1 initiates the majority of the
iological activities resulting from TNF- [127]. TNFR1 (p60) is
xpressed in all cell types whereas TNFR2 (p80) is expressed mainly
n immune cells [128]. Only TNFR1 contains the death domain
DD) (i.e., TNFR2 does not contain the DD) making it an important
ember of the death receptor family that is capable of inducing
poptotic cell death [129].
Aside from death inducing activity, TNFR1 also has the ability
o transduce cell survival signals. Binding to the homotrimer TNF-
, TNFR1 trimerizes the silencer of death domain (SODD) protein
hat is released [130]. The TNFR-associated domain (TRADD) binds
o the DD of TNFR1 and recruits other adaptor proteins includ-
ng the receptor interacting protein (RIP), TNFR-associated factor
 (TRAF-2), and Fas-associated death domain (FADD) [131]. These
daptor proteins, in turn, are responsible for downstream cellular
ignaling. Apoptotic signaling mediated by TNFR1 results in FADD
inding to caspase 8 and its activation. The chain of events leads to
roteolytic activation of caspase enzymes and involves the mito-
hondrial cytochrome c release [132], which leads to the activation
f endonucleases and DNA fragmentation.
Alternatively, TNFR1 may  signal survival processes by recruit-
ng TRAF-2 to the complex. TRAF-2 inhibits apoptosis by association
ith the cytoplasmic inhibitor of the apoptosis protein (cIAP). Once
RAF-2 associates with TNFR1, cell survival pathways are initi-
ted through a series of phosphorylation steps resulting in the
ctivation of cFOS/cJun transcription factors by MAPK and cJun
-terminal kinase (JNK) [133,134]. Activation of TRAF-2 and RIP
s associated with activation of the NF-B transcription factor
ia a complex of NF-B-inducing kinase (NIK) and an inhibitor,
B kinase (IKK) [135]. The activation of cFos/cJun and NF-B
ranscription factors mediates the transcription of anti-apoptotic,
roliferative immunoregulatory, and inﬂammatory genes. NF-B is
he main survival transcription factor that prevents TNF--induced
poptosis, so NF-B inhibition may  be an efﬁcient strategy for
poptosis-inducing cancer therapy [135–137].
Inhibition of NF-B is known to sensitize cancer cells to TNF-
reatment [138,139]. Furthermore, it has been shown that NF-B-
nduced expression of iNOS increases cancer cell survival [140,141].
nhibition of NOS can potentially sensitize cancer cells to TNF-
reatment. ROS are generated by TNF--mediated apoptotic events,
hile NF-B induces expression of ROS-neutralizing enzymes
ike superoxide dismutase [142]. Recent data also show that the
RNA-decay protein tristetraprolin (TTP) interacts with TNFR1
n a TRAF2-mediated fashion initiating cJun-kinase activation.r Biology 35 (2015) S151–S184
Inhibition of TTP ubiquitination results in enhanced TNF-induced
apoptosis in cervical cancer cells [143].
The role of TNF- in carcinogenesis is controversial. While high
concentrations of this cytokine display antitumoral response in
murine model of sarcoma [144], low sustained TNF- levels can
induce a tumor phenotype [145]. The TNF- tumor promoting
mechanism is based on ROS and RNS which can induce DNA damage
and facilitate tumorigenesis [146–148]. TNF--mediated inﬂam-
mation has been linked to cancer; for instance, a recent report
shows that H. pylori strains produce TNF--inducing protein (Tip-
), a carcinogenic factor in gastric epithelium. H. pylori isolated
from gastric cancer patients secreted large amount of Tip-, which
is incorporated into gastric cancer cells by cell surface nucleolin,
a Tip- receptor. The nucleolin-Tip- binding induces TNF- and
other cytokine genes expression and results in NF-B activation.
Similarly, TNF- through TNFR1, Noxo1, and Gna14 signaling leads
to H. pylori-mediated gastric tumorigenesis [149]. These events are
also associated with epithelial to mesenchymal transition (EMT) in
human gastric carcinogenesis [150].
Direct evidence also points to the role of TNF- in the metastatic
cascade. Administration of TNF- leads to signiﬁcant increase of the
number of lung metastases [151]. Conversely, tumor cells activate
myeloid cells to generate a microenvironment favorable for metas-
tasis. In Lewis lung carcinoma (LLC) cells-conditioned-medium,
high levels of IL-6 and TNF- were induced in bone marrow-
derived macrophages [152], and TNF-−/− but not IL-6−/− mice
injected with LLC cells showed improved survival and reduced
lung tumor multiplicity, suggesting a critical role of TNF- in
LLC metastasis [152]. Others report that TNF--deﬁcient mice are
resistant to tetradecanoyl-phorbol-13-acetate-(TPA) induced skin
carcinogenesis [153]. The role of TNF- in angiogenesis was also
studied recently, and Fajardo et al. [154] showed that high TNF-
 doses inhibited angiogenesis in mice subcutaneously implanted
with angiogenesis disk-system, an experimental strategy used to
induce new blood vessels, while low loses promoted vasculariza-
tion of the area. The antiangiogenic action of TNF- is related to
downregulation of ˛vˇ3 and the angiotensin signaling pathway
[155], while proangiogenic responses have been associated with
increased VEGF, VEFGR, IL-8, and FGF expression [156]. Further-
more, low TNF- increases tumor growth and induces angiogenesis
of diverse tumors in mice [157,158].
The effect of TNF- in induction of carcinogenesis, angiogenesis
and metastasis and invasion has therefore been supported by sev-
eral studies, so targeting TNF- and TNFR may  be a viable option
for treatment of cancer.
Recently several TNF- targeting drugs have also been used
mostly to treat inﬂammatory diseases. Examples include inﬂix-
imab, a recombinant IgG1 monoclonal antibody speciﬁc for TNF-
[159], Etanercept, a genetically engineered protein comprising two
molecules of the extracellular domain of TNFR2 (p75) and the Fc
portion of IgG1 [160], adalimumb, a monoclonal antibody of recom-
binant IgG1 [161], golimumab, a human anti-TNF-  monoclonal
antibody [162], and certolizumab, a humanized anti-TNF- anti-
body with high afﬁnity to TNF- [163]. However, major side effects
of these anti-TNF-  agents are infection (tuberculosis, varicella, and
other opportunistic infections) and malignancies especially when
TNF- antagonists are used concurrently with other therapies
[164,165]. For example, a subset of patients with inﬂammatory dis-
eases may  also have an increased risk of non-Hodgkin’s lymphoma
(NHL) [166], therefore treating these patients with anti-TNF- may
increase the rate of lymphoma [167–169]. Skin cancer has also been
reported as a side effect in some studies involving TNF- blocking
[170,171].
So, although TNF- is a cytokine with well-known anticancer
properties that has been utilized as an anticancer agent for the
treatment of some patients with locally advanced solid tumors
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172], its promise as a constituent within a multipronged approach
imed at a broad-spectrum of targets will need to be carefully
ssessed in light of these divergent outcomes.
.5. iNOS
iNOS has been of interest in cancer since the discovery of
ts metabolite, nitric oxide (NO) in the 1990s. Over the years,
xperimental data highlighted iNOS overexpression as a pivotal
vent ensuring tumor growth [173]. Indeed, more than 2000 peer-
eviewed publications support the iNOS-NO axis as a potential
arget in cancer. Under normal physiological conditions, NO is pro-
uced by the constitutive forms of NOS (cNOS and eNOS) and
odulates pivotal cellular processes, such as vasodilatation, cell
urvival and growth. However, in chronic inﬂammatory conditions,
he iNOS-NO axis is upregulated, and quickly yields NO-derived
pecies with strong nitrosative properties, especially when other
eactive species are also produced (such as the superoxide anion).
nce formed, NO-derived species can quickly react with all cellu-
ar components, including proteins, lipids and DNA. Therefore, the
ain carcinogenic effect of NO-derived metabolites is related to
heir capability to potentiate genomic instability, as induced by the
NS peroxynitrite [174].
Experimental data and in vitro studies have supported iNOS
s a viable target by demonstrating its overexpression in virtu-
lly all types of cancer cells, including glioma [175], hepatoma
176], mastocytoma [177], melanoma [178], B-cell lymphoma
179], neuroblastoma [180], mammary adenocarcinoma [181], and
varian carcinoma [182], among others. In the same way, iNOS up-
egulation has been documented in human cancerous tissues such
s glioblastomas [183], brain tumors [184], prostate carcinoma
185], esophageal adenocarcinomas [186], B-cell CLL [187], pri-
ary lung cancer [188], transitional cell carcinoma of the bladder
189], pancreatic cancer [190], thyroid papillary carcinomas [191],
uccal squamous-cell carcinomas [192], melanoma [193], colon
arcinoma [194], gastric cancer [195], breast cancer [196], stom-
ch cancer [197], malignant mesotheliomas and metastatic pleural
denocarcinomas [198], hepatocellular carcinoma [199] and ovar-
an carcinoma [200]. The enhanced activity and expression of iNOS
n cancer cells seems to be a necessary mechanism for generating
igh levels of NO and its derived species, which promote genomic
nstability [201], cancer growth [202], and spreading [203]. There-
ore interfering with this enhanced NO-iNOS machinery may  rep-
esent a putative target for pharmacological intervention in cancer.
Interfering with the NO dynamic is not a simple task. In cancer,
O can be derived from both host and tumor cells [204]; therefore,
locking tumor-iNOS has potential implications for healthy cells.
he mode of therapeutic delivery therefore needs a degree of speci-
city for cancerous cells (e.g., nano-carriers targeting membrane
eceptors unique to cancerous cells). In this context, strategies may
e directed against (a) iNOS activity, (b) iNOS-derived NO and (c)
ainstream regulators of iNOS expression. Regarding the iNOS-
O axis, experimental approaches have been exploited to either
lock iNOS or to scavenge NO in cancer models, and interventions
nclude treatment with aminoguanidine [197], N(G)-nitro-l-
rginine methyl ester [205], carboxy-PTIO [206], tyrosine-kinase
nhibitors [207], TGF--like molecules [208], S-methylisothiourea
ulfate [173] and some natural compounds [209].
Interventions of the mainstream regulators of iNOS expres-
ion may  be quite difﬁcult because there are so many molecules
nvolved in inﬂammation. It has been demonstrated that cancer-
elevant mediators could include IL-1 [210], TNF- [211], NF-B
209] and STAT-1 [212], among others. In fact, NO blockage
as reached promising results in experimental models, inhibi-
ing tumor growth [213], prolonging survival [214], and reducing
etastasis [215]. These data indicate that the pharmacologicalr Biology 35 (2015) S151–S184 S157
impairment of iNOS functioning may  be useful in patients diag-
nosed with metastatic disease, since sustained high levels of
systemic NO are reported in such patients [216–219].
Clinical trials have tested the efﬁcacy and safety of iNOS
inhibitors in humans, and have provided support to encourage the
use of such drugs in cancer, with no important adverse effects
[220–222]. Vital functions such as blood pressure, pulse rate, or
respiratory function – all pivotal functions physiologically con-
trolled by NO – did not change after the systemic administration
of the iNOS inhibitor l-N6-(1-iminoethyl)lysine 5-tetrazole amide
(SC-51) on healthy volunteers [220]. In the same way, the use of
nebulized aminoguanidine was tested in healthy individuals and
patients with pulmonary diseases, and no adverse effects were
reported regarding cardiovascular functioning after NO blocking
[221,222]. Although the evidence is promising, in-depth studies
still need to be conducted to conﬁrm that iNOS blockage will stop
tumor growth without compromising normal functions that are
dependent on NO.
In theory, interfering with the NO-axis could also affect immune
function. For example, experimental knockout of iNOS enhances
the mortality of mice in sepsis [223]. However, there is no evi-
dence of immunosuppression after iNOS blockage in cancer models
and none of the clinical trials using NO-blockers have reported on
immunosuppressive effects [220–222].
2.6. AKT
Protein kinases are an important family of regulatory enzymes
required for the growth, division, and differentiation of cells, and
they have been closely examined as possible mediators of onco-
genesis. In particular, the kinase signaling pathway known as the
phosphatidylinositol 3-kinase/protein kinase-B/mammalian target
of rapamycin (PI3K/AKT/mTOR) represents one of the intracellular
cascades of utmost importance when examining cellular prolifer-
ation, differentiation, as well as cytoskeletal reorganization. The
dysregulation of this pathway can direct the cell towards carcino-
genesis [224].
AKT was  initially deﬁned by three groups in 1991, Bellacosa
et al. [225], Coffer et al. [226], and Jones et al. [227]. It possesses
tumorigenic potential, which normally remains downregulated via
the phosphatase and tensin homologue (PTEN) gene [224,228,229].
However, mutations in the PTEN gene, which are found in several
human malignancies, lead toward the inhibition of AKT downregu-
lation, which would normally occur through the dephosphorylation
of PIP3, a product of PI3K activation [229,230]. The increased poten-
tial for cellular proliferation leading toward tumorigenesis initiated
through PKB activation may  also result from a response toward
various cellular stimuli, such as heat shock, osmotic, and oxida-
tive stress [229]. Mechanistic research has revealed a wide range
of inﬂuences [231], including critical roles by AKT in proliferation
[232], resistance to apoptosis [233], glucose metabolism [234], cell
migration [235], and the regulation of autophagy [236].
From an inﬂammation standpoint, studies of the role of AKT
in phagocytosis, bacterial infections, LPS tolerance, production of
proinﬂammatory cytokines, and migration during macrophage-
mediated innate immunity strongly suggest a pivotal role in the
functional activation of macrophages [237]. Evidence suggests that
AKT promotes NF-B activation [238]. In vivo tests on rodents
(rat paw edema) also suggest that AKT inhibitors prevent AKT
phosphorylation and downregulate the expression of inﬂammatory
factors IL-6, MCP-1, TNF and iNOS [239]. Similarly, in research on
pancreatitis, researchers have found that AKT inhibition mediates
a reduction in the activation of NF-B and p38MAPK activity in SAP
rats and a downregulation of NF-B-dependent proinﬂammatory
genes, including TNF-, IL-1 and IL-6 [240].
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From an immune perspective, PI3K-Akt pathway inhibitors are
lso attractive for their ability to selectively inhibit regulatory
 cells (Tregs) with minimal effect on conventional T cells. In
any cancers, an important tumor immune-evasion mechanisms
nvolves the effects of suppressive immune cells, speciﬁcally regu-
atory T cells (Treg). So the depletion of Tregs has been found to be
n effective strategy to enhance the immune response, but selec-
ive depletion of these suppressive cells (i.e., without affecting other
mmune cells) has not been very successful. Notably, however,
I3K-Akt pathway inhibitors selectively inhibit Tregs with minimal
ffect on conventional T cells (this has been shown in both human
nd murine CD4T cells) and in vivo treatment with these inhibitors
esulted in a signiﬁcant and selective reduction in Tregs in both
aïve and tumor-bearing mice (combined with a signiﬁcant thera-
eutic antitumor effect). So PI3K-Akt pathway inhibitors appear to
epresent a promising approach to deplete Tregs in cancer [241].
Consequently, AKT inhibition is being aggressively pursued as a
ew therapeutic strategy for a range of cancer types, including ovar-
an [242], breast [243], lung [244], and bladder [245]. PI3K and AKT
nhibitors are still in the early stages of development, but despite
hree generations of compounds targeting PI3K already having
een developed, none have proved efﬁcacious, mainly due to the
mergence of therapeutic resistance [246,247]. It is our opinion
hat this particular target, which appears to have strong promise,
ay  still prove to be more effective when acted upon with a range
f other therapeutic constituents that can address the alternate
athways that might otherwise serve to support this resistance.
.7. CXC chemokines
Chemokines were originally characterized by their ability to reg-
late the directional migration of leukocytes to inﬂammatory sites.
his observation has key implications for tumorigenesis, as inﬂam-
atory cell inﬁltration is a common feature of many cancers and
as varied functional consequences.
Chemokines or chemotactic cytokines are a group of small
8–14 kDa) heparin-binding proteins that interact with cognate
ell-surface receptors and play important roles in a number of
hysiological processes such as development, host immunity, and
ellular trafﬁcking [248]. These functionally related small secreted
roteins constitute the largest cytokine family in humans [249].
hemokines contain cysteine residues at their N-terminus and the
osition of these amino acids forms the basis for classiﬁcation into
our major groups: CXC, CC, CX3C or C [248]. Most chemokines har-
or a four-cysteine motif internally linked by disulﬁde bonds at
onserved sites.
The mechanism whereby chemokines exert biological effects
elies on their ability to bind to the extracellular domain of G
rotein-coupled chemokine receptors, which leads to production
f second messengers, cytoplasmic calcium mobilization, and the
ctivation of multiple downstream signaling cascades, including
he PI3K/AKT pathway, the Ras/MAPK axis, and the Janus kinase
JAK)/STAT cascade [250]. Chemokines are produced by leukocytes,
ndothelial cells, ﬁbroblasts, epithelial cells, and tumor cells [251].
his section will be limited to a discussion of CXC chemokines.
Chemokines produced by neoplastic and/or stromal cells con-
rol the nature of the inﬂammatory inﬁltrate by actively recruiting
ells of the innate and adaptive immune systems [249]. The ability
o regulate cell trafﬁcking in and out of the tumor milieu has diverse
nd complex functional consequences. Some chemokines promote
onditions favorable for tumor growth and progression, while oth-
rs have antitumor activity [252]. For example, IL8/CXCL8 induces
eukocyte cell migration during inﬂammation, and this response
an promote tumor growth and development by generating a favor-
ble microenvironment [252,253].r Biology 35 (2015) S151–S184
In contrast, chemokines such as CXCL10 can have angiostatic
properties owing to their ability to attract antitumoral lympho-
cytes via the receptor CXCR3. The extents to which chemokines
recruit immune cells to tumor sites have dramatic, often opposite,
functional effects. Indeed, chemokines recruit tumor-associated
macrophages (TAM) that promote tumor progression, but when
TAMs are recruited massively and appropriately activated, they
can exert antitumor activity [249]. Neutrophils, lymphocytes
and dendritic cells commonly are recruited to tumors such as
bronchioloalveolar carcinomas, colon adenocarcinomas, myxoﬁ-
brosarcomas, gastric carcinomas, and melanomas, where they can
have pro- and antitumorigenic effects [254–261]. However, the
presence of NK cells is relatively infrequent in tumors and their
presence consistently correlates with good prognosis and increased
survival [262,263].
In addition to their role in cell migration and inﬂammation, the
chemokine/chemokine receptor system impacts development and
progression of malignant diseases by regulating tumor initiation,
growth, survival, migration, adhesion, invasion, angiogenesis, and
metastasis [248,253]. In summary, chemokines and their receptors
regulate tumorigenesis directly by acting on tumor cells, and indi-
rectly by regulating the composition of the inﬂammatory inﬁltrate.
The diversity of the chemokine/chemokine receptor system is such
that it can both contribute to, and inhibit, key events relevant to
the tumorigenic process.
CXC chemokines and their receptors are often over expressed
in a variety of tumors, affecting proliferation, motility, cell survival
and resistance to chemotherapeutic drugs [264–266] Chemokine
receptors, unlike other cell surface receptors, are also promiscuous
as they bind multiple ligands (chemokines), they can function in
ligand-independent manners, and they can elicit multiple effects
following binding to a single CXC chemokine [264,267]. For exam-
ple, each of the two  cell surface receptors of IL-8, CXCR1 and CXCR2
has diverse functions. IL-8 binding to CXCR1 results in activation
of mitogenic signaling and increased ERK1/2 MAP  kinase activ-
ity. CXCR2 mediates angiogenesis, motility, invasion and activation
of NF-B mediated cell survival pathways [267,268]. Some recep-
tors, e.g., the CXCL12 co-receptor CXCR7, also binds CXCL11 and
MIF, and activates EGFRs independently of their ligands [269–272].
These complex and diverse functions of CXC chemokines and their
receptors present signiﬁcant challenges for cancer therapy, but also
opportunities for investigating novel targeted approaches.
Chemokines and their receptors are regarded as promising
molecular targets for therapeutic intervention. Several antagonists
of CXCL8-CXCR1/CXCR2-mediated signaling are in development,
including neutralizing antibodies, orally active small-molecule
antagonists (e.g., SCH-527123, SCH-479833 [273]), and adenoviral-
mediated anti-sense gene transfer approaches [274,275]. Studies
have shown that chemokines and their receptors are closely linked
to emergence of drug-resistant cancer stem cells following regu-
lar chemotherapy exposure [276]. Use of small molecule inhibitors
of IL-8 binding to CXCR1, such as repertaxin, has been shown
to enhance responses to chemotherapy in breast cancer [277].
Identiﬁcation of the CXCL12-CXCR4/CXCR7 axis as a novel thera-
peutic target led to development of several therapeutic approaches
[248,278]. Examples of these are the anti-CXCR4 drug AMD3100
[279], the CXCL12 analog CTCE-9908 [280–282], the anti-CXCL12
aptamer NOX-A12 [283], the inhibitor of CXCR4 expression chal-
cone 4 [284], and the CXCR7-speciﬁc inhibitors CCX2066 [278,283],
CCX733 [285] and CCX754 [286,287]. CXCR4 also has been tar-
geted using monoclonal antibodies and small molecule antagonists
[288–291]. In addition, administration of recombinant forms of
chemokines with angiostatic and/or antitumorigenic effects such as
CXCL4, CXCL9, and CXCL10 has been proposed as a potential strat-
egy to inhibit tumor growth and limit spreading [252,292–295].
Thus, currently there are several chemokines that are targets of
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herapy, such as CXCL-1, CXCL8 and CXCL12 and others in various
tages of development [296,297].
The intrinsic functional redundancy in the chemokine system
uggests that blocking a single receptor upregulated in a particular
umor is unlikely to signiﬁcantly affect the integrity of protective
mmune mechanisms. The redundancy of this system itself presents
herapeutic challenges related to possible overlapping functions of
ultiple receptors, but this feature also offers attractive opportu-
ities from a therapeutic standpoint. It may  be possible to ﬁne-tune
xperimental screening studies to identify agents that inhibit cer-
ain signaling pathways while sparing others. The ability to bias
ignaling responses opens the possibility of selectively targeting
vents that contribute to disease while preserving immunity. In
ddition, the receptor microenvironment can profoundly affect its
unction and downstream signaling, and there may  be serendipi-
ous and unique speciﬁcities built into target cancer cells that can
e capitalized upon to maximize beneﬁcial therapeutic action and
inimize or block the loss of beneﬁcial responses such as antitumor
mmunity [298].
Many recent studies have revealed that chemokines can reg-
late the movement of a wide variety of immune cells including
ymphocytes, NK cells, and dendritic cells in both physiological
nd pathological conditions. So these features endow chemokines
ith crucial roles in immune responses [299]. But therapeutic
pproaches that focus on chemokines can produce a range of
mmune-related effects. For example, a recent study demonstrated
n several murine models of anthracycline-based chemotherapy
hat the inhibition of CCL2 or CCR2 might actually impair the
nticancer immune response [300]. On the other hand, there are
ther chemokines that appear to have the potential to enhance the
ecruitment of antigen presenting cells and effector cells to sites
here they are needed [301]. Given the range of chemokines and
he complexity of the immune system, readers who  are seeking
ore detail on this topic are encouraged to peruse several recent
eviews that cover this topic in considerable detail [299,302,303].
ufﬁce to say that although the development of therapeutics based
n targeting chemokines and their receptors has been challenging,
ut the lessons learned are leading to advances that should allow us
o develop more reﬁned strategies with better chances of success.
. Low toxicity approaches
Several synthetic antiinﬂammatory molecules have been tested
n cancer research with important preclinical results; however, the
ranslation to clinical practice has been hampered by the abrupt
nding of unpredictable serious side effects or by a lack of signiﬁ-
ant anticancer activity when tested in humans. For example, the
se of nonsteroidal antiinﬂammatory drugs (NSAIDs), in particular
spirin, have been included as a factor in several epidemiologi-
al studies, and also clinical trials have been attempted in order
o demonstrate chemopreventive activity. While epidemiological
ata do show association between long term ‘baby aspirin’ intake
nd colon cancer risk [304], many of the clinical trials designed
o look for prevention of the onset of cancer or of pre-cancerous
esions have not reached satisfactory results for a variety of rea-
ons (such as problems with the target population, duration of
he study, and more importantly, side effects [305–308] that range
rom gastrointestinal bleeding to hemorrhagic stroke). Thus, the
se of NSAIDs in clinical practice for cancer chemoprevention has
lways been outweighed by the possibility of serious complica-
ions.At the same time, a wide spectrum of phytochemicals, present in
dible, non-edible and medicinal plants, and endowed with potent
ntiinﬂammatory properties, have been shown to prevent tumor
ccurrence in several organs of experimental animals and inhibitr Biology 35 (2015) S151–S184 S159
the growth of neoplastic cells [309–315]. Indeed, several epidemi-
ological and experimental studies provide convincing evidence
that there exists a strong relationship between increased con-
sumption of various vegetables, fruits, whole grains, legumes and
spices and a decrease in cancer risk [316–319]. A large number of
phytochemicals present in dietary sources are capable of suppress-
ing carcinogenesis through inhibition of inﬂammatory cascade
[320–322] as well as modulation of various signaling pathways
implicated in cancer initiation, promotion and progression. We
have therefore focused on the following chemicals from plants and
foods as promising approaches with therapeutic potential to reach
the targets that we  have identiﬁed: curcumin, resveratrol, epigal-
locatechin gallate (EGCG), lycopenes, anthocyanins, and genistein.
3.1. Curcumin
Curcumin, (diferuloylmethane) is a component of golden spice
Curcuma longa (commonly known as turmeric) which has been
used for centuries in many Asian countries as part of diet or as a
coloring agent. The anticancer and antiinﬂammatory effects of cur-
cumin have been demonstrated in many cell and animal studies,
and recent research has shown that curcumin can also target cancer
stem cells [323], which makes it a dietary substance of considerable
interest.
In Nepal and India, where daily curcumin uptake in diet has been
assessed as high as 50–100 mg/day, no toxicities or adverse effects
have been reported at the population level [324,325]. The National
Toxicology Program of the National Institutes of Health evaluated
the toxicology and carcinogenic effects of turmeric in 1993 at a dose
of 0.2 g/kg/day (CAS no. 8024-37-1) for 13 weeks and 2 years on rats
and mice. No adverse toxicological effects and no histopathological
changes in treated mice were found. Similarly, in a study under-
taken by National Cancer Institute in the United States, the oral
administration of 3500 mg/kg body weight curcumin for 90 days in
rats, dogs, or monkeys did not cause any adverse effects and was
well tolerated [326]. In 1996, the Food and Drug Administration of
the United States recognized curcumin as a Generally Recognized
As Safe (GRAS) compound [327]. Up to 1000 mg/kg/body weight
oral administration of curcumin did not have any adverse effect
on reproduction of rats, when fed for two  successive generations
[328]. Finally, in humans, a dose escalation study performed in 24
adults, found that single oral doses up to 12 g were well tolerated
and the observed adverse effects were not dose-related. Curcumin
supplementation up to 8 g/day for three months was well tolerated
in the patients with precancerous conditions or non-invasive can-
cer [329], and in another clinical trial in patients with advanced
colorectal cancer, curcumin supplementation ranging from 0.45
to 3.6 g/day for four months was well tolerated by subjects
[330].
However, curcumin may have adverse effect in the following
situations: (a) curcumin increases contraction in the gallbladder
and potentially could increase the risk of symptoms in people with
gallstone [331,332]; (b) curcumin can increase the risk of bleeding
in subjects taking anticoagulant medicines because it can inhibit
platelet aggregation [333,334]; and (c) curcumin also increases
acid output in the stomach and can interfere with acid suppressing
drugs in patients with duodenal ulcers [335].
Curcumin has garnered signiﬁcant interest in cancer research
because it can regulate signaling pathways that are dysregulated
during tumorigenesis, including proliferation, differentiation, inva-
sion, apoptosis, and cell cycle checkpoints [336]. In vitro studies
indicate that curcumin can target numerous kinases, phosphatases,
and enzymes [337]. For example, curcumin can inactivate NF-B
[338], and reduce COX-2 expression [339] and downstream targets
as well [338]. It promotes apoptosis through interaction with p53
[340] and by increasing caspase expression [341], and it induces
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ell cycle arrest [342]. In animal models curcumin prevents can-
er development through reduction of TNF-, interferon- (IFN-),
nd COX-2 [343]. So the diverse biological effects of curcumin make
his compound an attractive constituent therapeutic that has been
idely evaluated for its anticancer activity [344].
Indeed, curcumin has been shown to inhibit the development
f chemically induced tumors of the oral cavity, forestomach, duo-
enum, and colon of experimental animals [337]. For example, the
ombination of 480 mg  of curcumin and 20 mg  of quercetin (three
imes daily) for six months reduced the number of polyps in a
mall number of familial adenomatous polyposis (FAP) patients
ithout major side effects [345]. Similarly, 4 g of curcumin daily
or 1 month prevented the development of aberrant crypt foci in
umans [346]. A preclinical study also suggests that curcumin could
ork as chemotherapeutic agent, by enhancing colon cancer cells
ensitivity to oxaliplatin [347]. However, not all trials have been
uccessful [348], and the systemic bioavailability of curcumin is
xtremely poor [349]. Nonetheless, at the US National Institutes
f Health website (https://clinicaltrials.gov), there are 47 ongoing
linical trials with curcumin registered for different types of can-
ers, but most of them appear to be preclinical or pilot studies. For
ormal validation of the efﬁcacy of curcumin as a chemopreventive
r chemotherapeutic drug, randomized, placebo-controlled, and
ouble-blind trials are required.
Chemical and photochemical instability/degradation, absorp-
ion, metabolism, and excretion of the curcumin are considered
he reason for low systemic bioavailability in human subjects [350].
hen curcumin was administered orally at a dose of 1000 mg/kg
n rats, the majority of the curcumin was excreted in feces and
egligible amounts were detected in the urine [351]. Curcumin
s bio-transformed in the intestine, and the liver converts it into
lucuronides and curcumin sulfates [352,353]. Also, reduction
f the curcumin to tetrahydrocurcumin and hexahydrocurcumin
as been reported after oral administration in rats, mice, and
uman [353–355]. Even intravenous and intraperitoneal admin-
stration of curcumin in rats resulted in reduced curcumin and
ubsequently reduced curcumin converted to monoglucuronide
onjugates [354]. Transformation of curcumin may  result in loss of
he biological activity of curcumin [353]. In pharmacokinetic and
ynamic studies, serum curcumin concentrations peaked in 1–2 h
356]. The peak serum concentrations of curcumin were 0.5, 0.6,
nd 1.8 M/liter following an oral dose of 4, 6, and 8 g of curcumin,
espectively [356].
Although systemic availability of curcumin is very low, it has
een shown in some studies that orally administered curcumin
ccumulates in gastrointestinal tissues [357,358]. It has been
eported that when colorectal cancer patients were administered
.6 g/d of curcumin orally for seven days, curcumin was  detected in
ormal surgical samples of colorectal tissue [357]. Recent advances
hat use implantable polymeric micelles as nano-delivery systems
r phospholipid-based delivery systems for curcumin increase its
ccumulation in organs speciﬁcally in the gastrointestinal tract,
hat can target COX-2 as well as prostaglandin synthesis pathway
ore effectively [359–362]. In vitro, curcumin shows potential as
 COX-2 inhibitor, inhibiting the expression of COX-2 mRNA and
nzymatic activities of COX-2 protein in colonic epithelial and in
acrophages [363,364]. Curcumin also inhibited the expression of
OX-2 mRNA and enzymatic activities of COX-2 protein in colonic
pithelial and in macrophages [363,364].
Because curcumin can target prostaglandin biosynthesis, it can
e used in cancers where COX-2 activation plays an important
ole. New advancements in in vivo delivery systems of curcumin
ill result in a higher levels of curcumin accumulation in organs
speciﬁcally in the gastrointestinal tract) that can target COX-2
s well as prostaglandin synthesis pathway more effectively. Cur-
umin inhibited bile acid and phorbol ester induced COX-2 mRNAr Biology 35 (2015) S151–S184
expression in gastrointestinal epithelial cells [365]. In mouse skin
cells, curcumin inhibits phorbol ester-induced expression of COX-2
[348]. In a human non-small cell lung cancer ectopic and orthotopic
xenograft mouse model, curcumin reduced COX-2 expression in
subcutaneous tumors in vivo and caused a 36% decrease in weight
of intralung tumors accompanied by a signiﬁcant survival rate
increase [366]. Curcumin inhibition of COX-2 in NSCLC cells was
associated with decreased survival [366].
Notably, in vitro treatment of curcumin also suppressed CXCL-
8 production by human pancreatic carcinoma cell lines and
downregulated the inﬂammatory cytokines CXCL1 and CXCL2
in breast cancer cells via NF-B [367,368]. In a Kras-mediated
lung cancer model in mice, curcumin inhibited the expression
of neutrophil chemoattractant keratinocyte-derived chemokine
CXC-KC and subsequently inhibited progression of the cancer
[369].
From an immune perspective, curcumin suppresses the type 1
immune response, which can increase susceptibility to infection
[370]. But at the same time curcumin appears to act in a supportive
manner for tumor-related immune effects. For example, in in vitro
tests aimed at studying the role of curcumin in the prevention of
tumor-induced dysfunction of T cell-based immune response, cur-
cumin prevented the loss of T cells, expanded central memory T
cell (T(CM))/effector memory T cell (T(EM)) populations, reversed
the type 2 immune bias and attenuated the tumor-induced inhibi-
tion of T-cell proliferation in tumor-bearing hosts. Curcumin also
inhibited the suppressive activity of Treg cells (by downregulat-
ing the production of TGF- and IL-10) and enhanced the ability
of effector T cells to kill cancer cells [371]. As well, curcumin sig-
niﬁcantly inhibited the induction of IDO expression (a key enzyme
in T-cell suppression-mediated immune tolerance to tumors) and
activity by IFN- in bone marrow-derived DCs, which appears to be
an important immunomodulatory property of curcumin that may
serve to strengthen its therapeutic potential [372].
3.2. Resveratrol
Resveratrol (3,5,4′-trihydroxystilbene), a compound found in
the skins of red grapes, red wine, berries, peanuts and many other
plants, has been shown to possess health-promoting properties. It
is a bioactive polyphenol and has antiinﬂammatory, antioxidant,
antimicrobial, anticancer, neuroprotective, and cardioprotective
effects. Numerous preclinical animal studies provided encourag-
ing evidence for cancer chemopreventive and chemotherapeutic
potential of this phytochemical [373]. In vitro evidence of resvera-
trol efﬁcacy is well described; however, many concerns regarding
its effectiveness in vivo arise from its poor stability and rapid
metabolism and bioavailability following oral ingestion. Peak
plasma concentrations occur at around 1hr, and levels of the parent
compound are very low [374,375]. Adverse effects are mild, even
at high doses (up to 5 g daily) [376]. Resveratrol works in animal
models [377] and humans; although the data for humans is more
sparse and controversial [378,379].
Resveratrol has been shown to have efﬁcacy in multiple animal
models of chronic inﬂammatory diseases. These diseases include
hepatitis [380], esophagitis [381], and in particular, there are many
conﬁrmed studies that resveratrol suppresses colitis [382,383] and
pancreatitis [384–386]. Resveratrol targets many of the key play-
ers involved in inﬂammation, prevents DNA damage, and induces
apoptosis in a p53-dependent manner [387–389]. Interestingly,
resveratrol can induce the expression of the p53 target, NAG-1
[non-steroidal antiinﬂammatory (NSAID) drug-activated gene-1],
a member of the transforming growth factor-beta superfamily,
that has pro-apoptotic and antitumorigenesis activities [390]. Also,
resveratrol prevents pRb hyperphosphorylation and thus the inac-
tivation of this tumor suppressor protein. Resveratrol also inhibits
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MP-2 [391] and MMP-9 [392,393], COX-1 [394], proinﬂammatory
ytokines [395–397], and growth factors such as hepatocyte growth
actor [398].
Additionally, resveratrol has potent NF-B-dependent antiin-
ammatory and chemopreventive effects both in vitro and in vivo,
nd impacts multiple disease phenotypes in a favorable manner.
or example, through the inhibition of NF-B, resveratrol amelio-
ates diabetic vascular inﬂammation and macrophage inﬁltration
n diabetic mice, inhibits the epithelial–mesenchymal transition,
odulates autophagy, suppresses cell transformation, regulates
iRNA levels, and reverses resistance to chemotherapeutic agents
399–405]. Notably, resveratrol has also been shown to inhibit
ther key modulators of inﬂammation and cancer discussed in
his review, including COX-2 [406–408], MIF  [409], TNF- [410],
NOS [411], AKT [412], and the CXC group of cytokines [413].
or example, Cichocki et al. showed resveratrol inhibited 12-O-
etradecanoylphorbol-13-acetate activated NF-B, AP-1, COX-2,
nd iNOS in mouse epidermis [414]. Similarly, Kundu et al. showed
hat resveratrol inhibits phorbol ester-induced expression of COX-2
nd activation of NF-B in mouse skin by blocking I-B kinase activ-
ty [408]. Dietary resveratrol (50–300 mg/kg) was found to inhibit
hemically induced hepatocarcinogenesis in rats with simulta-
eous suppression of hepatic iNOS, 3-nitrotyrosine, COX-2 and
F-B [415–417].
Several recently published clinical trials on resveratrol in
umans have shown that it exhibits antioxidant and antiinﬂam-
atory activities. It can improve glucose and lipid metabolism,
nd favorably modify a number of important pathways involved
n carcinogenesis (e.g., the insulin-like growth factor system [418],
poptosis [419] and others [420]). However, these effects can vary
nd depend on the protocols [376]. The plasma pharmacokinetics
f resveratrol in humans are also now reasonably well deﬁned, and
aily doses up to 1 g appear to be safe and well tolerated, although
astrointestinal toxicity is observed at higher intakes, and there is
otential for drug interactions at higher doses[420].
In some of the earliest research on resveratrol and immune
unction, Falchetti et al. [421] showed that in vitro exposure to
esveratrol produced a biphasic effect on anti-CD3/anti-CD28-
nduced development of both IFN- – IL2- and IL4-producing
D8+ and CD4+ T cells (with stimulation at low resveratrol con-
entrations and suppression at high concentrations). Similarly, it
as found to induce a signiﬁcant enhancement at low concen-
rations and suppression at high concentrations of both cytotoxic
 lymphocytes and NK cell cytotoxic activity [421], and this
iphasic modulation of NK cells has been conﬁrmed in more recent
esearch as well [422]. The administration of low doses of resver-
trol also inhibited Renca tumor growth with regulatory T cells
eing decreased, and a massive amount of activated CD8+ T cells
ccumulating in the tumor microenvironment. At the same time,
he expression of T-helper (Th)-2 cytokines (e.g., IL-6 and IL-10)
witched to Th-1 cytokines with dominance of interferon (IFN)-
, which increases the expression of Fas in Renca cells [423].
nd resveratrol has also been shown to suppress tumor-derived
D4+CD25+ regulatory T cells (which are a negative regulator of the
mmune system and main obstacles to cancer immunotherapy in
umor-bearing hosts) in mice [424]. And resveratrol at low and non-
ytotoxic doses has been shown to inactivate Stat3, preventing the
eneration and function of tumor-evoked regulatory B cells (tBreg),
ncluding expression of TGF- in mice. This frees antitumor effec-
or immune responses by disabling tBreg-induced conversion of
orkhead box protein (FOX)p3(+) Tregs (without nonspeciﬁc inac-
ivation of effector immune cells), which efﬁciently inhibited lung
etastasis in mice [425]. So the effects of resveratrol on the antitu-
or  capabilities of the immune system appear equally promising,
nd notably, this is accomplished with no apparent increase in sus-
eptibility to risks of infection.r Biology 35 (2015) S151–S184 S161
3.3. Epigallocatechin gallate (EGCG)
EGCG is the most abundant catechin in tea, is a potent antiox-
idant and antiinﬂammatory agent. It is found mainly in white tea,
green tea and, in smaller quantities, black tea. Despite the demon-
stration of cancer prevention by EGCG in many animal studies,
epidemiological studies have found mixed results concerning the
effectiveness of EGCG as a superior medicine for prevention and
therapy of cancer in humans [426]. Its limited in vivo activities
can be attributed to metabolism and bioavailability. Methylation,
glucuronidation, sulfation, and ring-ﬁssion metabolism represent
the major metabolic pathways for tea catechins [427]. It has also
been found that efﬂux transporters P-glycoprotein (Pgp), MRP1 and
MRP2 play roles in the absorption and excretion of green tea cat-
echins [428]. Several processes including intestinal metabolism,
microbial metabolism, hepatic metabolism and chemical degra-
dation are also involved in the fate of EGCG, resulting in its low
availability in animals, and most likely also in humans [429].
Isbrucker et al. conducted toxicity studies on EGCG. An oral
dose delivering 2000 mg  EGCG preparation/kg was lethal to rats,
whereas a dose of 200 mg  EGCG/kg induced no toxicity. The dietary
administration of EGCG to rats for 13 weeks was  not toxic at doses
up to 500 mg/kg/day. Similarly, no adverse effects were noted when
500 mg  EGCG preparation/kg/day was administered to pre-fed dogs
in divided doses. This dose caused morbidity when administered to
fasted dogs as a single bolus dose, although this model was consid-
ered an unrealistic comparison to the human condition. From these
studies a no-observed adverse effect level of 500 mg  EGCG/kg/day
was established [430].
There are multiple mechanisms that can explain the chemo-
preventive potentials of EGCG, among which are its ability to
affect cancer cell signaling pathways, suppress cellular prolifera-
tion and induce apoptosis [426]. The diversiﬁed effects of EGCG
may  explain its broad pharmacologic activities. With regards to
chronic inﬂammatory diseases associated with a high cancer risk,
EGCG has been shown to suppress colitis [431], hepatitis [432] (and
may  have antiviral properties against HBV and HCV [433,434]), and
pancreatitis [435] in animal models. Excitingly, in a pilot study
involving patients with mild to moderate ulcerative colitis, EGCG
(400–800 mg  daily) showed a therapeutic beneﬁt for patients who
were refractory to 5-aminosalicylic and/or azathioprine [436].
There is extensive evidence that EGCG targets key players in
inﬂammation, providing a mechanism of its efﬁcacy in vitro and in
vivo against chronic inﬂammatory diseases and associated cancers.
Noh et al. showed that EGCG improves Dermatophagoides pteroniss-
inus extract-induced atopic dermatitis-like skin lesions in a mouse
model by suppressing MIF  [437]. In addition, EGCG can inhibit TNF-
 [438], iNOS [439,440], AKT [441], the CXC group of cytokines
[442], and by reducing the transcriptional activity of NF-B, COX-
2 expression and PGE-2 synthesis [443–448]. Additionally, EGCG
activates wild-type p53 [449–451], and protects from p53 muta-
tion [452]. It promotes pRb hypophosphorylation and activation of
this tumor suppressor protein [453], and inhibits MMPs such as
MMP-9 [454].
In animal models EGCG prevents the development of adeno-
matous polyps in ApcMin/+ mice [455,456]. Some epidemiological
studies have shown that high consumption of green tea reduces
the risk of several types of cancers, including the lung, colorec-
tum, liver, esophagus and stomach [457,458]. High urinary levels of
tea polyphenol epigallocatechin (EGC) have been associated with
reduction of colorectal cancer among a Chinese population [459]
and a randomized clinical trial has shown a signiﬁcant reduction
in adenoma incidence among patients taking 1.5 g/day of green
tea extract [460]. Doses of green tea polyphenols greater than
800 mg/day increase in liver enzymes, and there is possible hepatic
toxicity in humans at this level [461–463]. Nonetheless, despite
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vidence from in vitro and non-human in vivo research on green
nd black tea as chemopreventive agents for colorectal cancer, data
re still insufﬁcient to conclude that either tea type is protective
464]. But EGCG does target and suppress many of the key players
nvolved in the inﬂammation-to-cancer sequence, and therefore
ay  be quite useful as a constituent within a mixture aimed at
nﬂammation in cancer.
From an immune perspective, EGCG signiﬁcantly suppressed
FN- production and the proliferation of peripheral blood
ononuclear cells in vitro [465]. It was also shown to exert antitu-
or  effects on colorectal cancer cells, at least in part by inhibiting
he expression and function of IDO through the suppression of
TAT1 activation [466]. In leukemic BALB/c mice that received 5,
0 and 40 mg/kg EGCG (orally) for two weeks, it increased the
ercentage of CD3, T-cell, CD19, B-cell, and Macrophage-3 antigen
Mac-3), and macrophages, but reduced the percentage of CD11b
monocyte) cell surface markers. It also promoted the phagocyto-
is of macrophages from 5 mg/kg treatment and promoted NK cell
ctivity at 40 mg/kg, increased T-cell proliferation at 40 mg/kg, but
lso promoted B-cell proliferation at all three doses [467].
At the same time, EGCG appears to have a protective effect
gainst bacterial infection. This was shown in EGCG treatment
f nicotine-suppressed macrophages where it reconstituted the
esistance to the infection and diminished a nicotine-induced inhi-
ition of cytokine production [468]. It was also demonstrated in
esearch against Pseudomonas aeruginosa and Escherichia coli iso-
ated from skin wounds [469], and against burn wound infection
y methicillin-resistant Staphylococcus aureus [470].
.4. Lycopene
Lycopene is a phytochemical that belongs to a group of plant pig-
ents known as carotenoids. Red colored lycopene is lipophilic and
aturally occurs in many fruits and vegetables. The richest sources
f lycopene are tomatoes and tomato products, however, apricots,
uava, watermelon, papaya, and pink grapefruit are also sources
f this phytochemical. Some studies suggest that cooking toma-
oes in oil may  increase the bioavailability of lycopene [471,472].
esearch, dating as far back as the 1920s, has shown that naturally
ccurring carotenoids, speciﬁcally beta-carotene, have anticancer
roperties. Since the late 1980s when it was recognized that the
ntioxidant activity of lycopene was twice that of beta-carotene
here has been a growing interest regarding lycopene as a possible
nticancer agent.
Only 10–30% of the lycopene in dietary sources can be absorbed
ia the human digestive system [473]. Although there is conﬂicting
ata, it has been suggested that lycopene is better absorbed when
aken in conjunction with fats due to its lipophilic properties [474].
nce ingested, lycopene is incorporated into lipid micelles and
bsorbed by the mucosa of the small intestine. The micelles are
hen transported to the liver as chylomicrons. Lipoproteins are the
arriers of lycopene in the blood stream and the means by which
ioactive lycopene gains access to the various organ systems. High
oncentrations of lycopene have been found in the testes, prostate,
drenal glands and liver [475].
Lycopene is a constituent of human diets that are rich in fruit and
egetables and epidemiological studies suggest that it may  have a
rotective effect against various cancers [476]. Lycopene is a pow-
rful antioxidant that blocks the action of free radicals which are
ctivated oxygen molecules that can damage cells and have been
hown to support the development of some cancers. For example,
umerous studies suggest that lycopene and lycopene rich natural
ietary products, when taken regularly, may  decrease the incidence
f a variety of malignancies including breast [477], ovarian [478]
ladder mouth, esophagus, pancreas [479] and colorectal cancer
480]. There is also great interest regarding lycopene and prostater Biology 35 (2015) S151–S184
cancer; about 30% of the published human studies (16/54) that have
considered lycopene concern prostate cancer. The association of a
diet rich in lycopene from tomato-based foods with a lower risk of
prostate cancer is supported by multiple studies [481–485].
Thus far, several researchers have investigated lycopene’s mech-
anism(s) of action as regards its anticancer effects. Oxidative
stress is a major factor implicated in chronic diseases and car-
cinogenesis. Lycopene has been found to increase the effects
of deoxiﬁcation proteins (such as epoxide hydrolase-1) and
protective enzymes (such as glutathione-S-transferase-omega-
1, peroxiredoxin-1 and sulphide-quinone oxidoreductase) [486].
Other studies have shown that lycopene downregulates the genes
that regulate proteins involved in the generation of ROS, including
ERO1-like protein-a and CLIC-1 [487]. In addition, lycopene may
prevent cancers, especially prostate cancer, via other mechanisms.
In vitro studies have shown that lycopene-induced activation of the
peroxisome proliferator-activated receptors (PPAR)-gamma-LXR
alpha-ABCA1 pathway is associated with decreased proliferation
of LNCaP prostate cancer cells [488,489]. When LNCaP cells were
exposed to lycopene, a dose-dependent decrease of the G0/G1
phase-related protein, cyclin D1, and an increase in the cyclin
kinase inhibitors, p53, p21 and p27 have been noted and were asso-
ciated with cell cycle arrest [490]. Other in vitro studies suggest
that lycopene may  induce apoptosis in human prostatic epithelial
cells. A protein expression proﬁling study revealed that lycopene
may  up-regulate pro-apoptotic proteins as well as downregulate
antiapoptotic proteins in human primary prostatic epithelial cells
in vitro [487]. Lycopene has also been shown to suppress the inva-
sion and migration of prostate cancer cells by downregulating the
expression of integrins [491].
Lycopene has also been shown to have antiinﬂammatory effects
in both in vitro studies that assessed macrophages as well as rodent
studies. In particular, lycopene has been associated with down-
regulation of TNF- gene expression and/or inhibition of TNF-
secretion in LPS stimulated macrophages [492–494]. Also, in a rat
model of pancreatitis, blood levels of TNF- were notably lower in
lycopene-treated versus control animals [495]. Similarly, decreased
TNF expression and secretion results have been noted in a num-
ber of endothelial cell in vitro studies [496,497]. Modulation of the
following signaling pathways have been proposed as the mecha-
nism of this antiinﬂammatory effects: ERK, NF-B, JNK, and HMGB1
[492–494,496,497].
It is not clear whether or not lycopene predisposes patients to
infections or immune system suppression. There is limited evi-
dence that lycopene and other carotenoids have antiinﬂammatory
effects that may  impact native immune function [492]. In some
of the earliest animal studies, intraperitoneally or intravenously
injected lycopene produced prolonged survival times in bacteri-
ally infected mice [498]. But according to Medfacts.com, a total of
143 lycopene drug adverse event reports were reported to the FDA
between January 2004 and October 2012, including 21 infectious
complications, but lycopene was  not thought to be the cause of the
infection in any of those cases (based on physician opinions – no
further details provided).
From an anticancer perspective, lycopene treatment promoted
promote spleen lymphocyte proliferation, and NK activity in vivo in
mice [499]. But another study on mice showed that lycopene signif-
icantly attenuates the maturation of murine bone marrow-derived
dendritic cells, and that it downregulated the expression of costim-
ulatory molecules (CD80 and CD86) and major histocompatibility
complex type II molecules, suggesting that it has immunosuppress-
ive potential [500].Studies in which lycopene was orally administered repeatedly,
for a period of time, did not identify any clear organ toxicity related
to the lycopene in rats or mice, however, in a dog, accumula-
tion of lycopene and vitamin A in the liver, and excess vitamin A
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n the kidneys were noted. Skin pigmentation and colored fatty
eposits in the liver were seen in a person who ingested high
arge amounts of lycopene daily over a period of years [501]. A
tudy concerning 20 male and 20 female Wistar rats that were
iven lycopene in their diets (a range of levels were assessed, the
ighest being 1% of diet) for 90 days showed no evidence of tox-
city based on: (1) clinical and neurobehavioral observations; (2)
otor activity assessment; (3) body weight and food consumption
easurements; (4) ophthalmoscopic examinations; (5) hemato-
ogy, clinical chemistry, and urinalysis; (6) organ weights, (7) gross
athology, or (7) histopathology [502].
Dietary lycopene, from eating fruits and vegetables, has no
nown side effects and is thought to be safe for humans. The opti-
um  dosage for lycopene has not been established, but the amount
ound helpful in studies generally falls in the range of 4–8 mg  daily.
atients in some studies who took a lycopene-rich tomato supple-
ent of 15 mg  twice a day had some intestinal side effects such as
ausea, vomiting, diarrhea, indigestion, gas, and bloating. Lycopene
t higher doses, especially when taken for long periods of time, has
een associated with diarrhea, fat buildup under the skin, chest
ain, heart attack, skin discoloration, stomach pain, stomach ulcer
rritation, vomiting, and worsened hot ﬂashes [503].
Supplements containing antioxidants such as lycopene may
nterfere with radiation therapy and chemotherapy if taken during
ancer treatment [504]. Even though studies have not been done
n humans, antioxidants are known to clear free radicals, which
ould interfere with one of the methods by which chemotherapy
nd radiation destroy cancer cells. Most of the human studies, thus
ar, have been case control or other types of observational studies
hich not as useful or predictive as clinical trials. More evidence
rom clinical trials is needed to conﬁrm that lycopene-rich foods
an help prevent or treat cancer. Further studies are needed to bet-
er document the beneﬁts and effects of lycopene supplements and
ts mechanism of action in vivo.
.5. Anthocyanins
A diet rich in polyphenolic anthocyanins (ACs) has been reported
s a chemoprotective agent in in vivo models by regulating
nﬂammatory cytokines. It inhibited the development of N-
itrosomethylbenzylamine-induced esophageal cancer in rats. The
nhibition was mediated through decreased expression of inﬂam-
atory biomarkers like COX-2, iNOS, p-NF-B, and soluble epoxide
ydrolase (sEH) and cytokine, pentraxin-3 (PTX3) expression [505].
C-rich black currant skin extract showed chemopreventive activ-
ty through downregulation of abnormal lipid peroxidation, protein
xidation, and expression of iNOS and 3-nitrotyrosine (3-NT) in
 dose-responsive fashion (100 and 500 mg/kg) and upregula-
ion of the gene expression of a number of hepatic antioxidant
Nrf2-regulated antioxidant pathway) and carcinogen detoxifying
nzymes, such as NAD(P)H:quinone oxidoreductase, glutathione-
-transferase, and uridine diphosphate-glucuronosyltransferase
soenzymes in diethylnitrosamine (DENA)-initiated hepatocar-
inogenesis in rats [506]. Black currant anthocyanins also abrogated
levated inﬂammatory markers, such as COX-2 and NF-B, during
ENA hepatocarcinogenesis in rats [507].
ACs also exerted an antiinﬂammatory effect in H. pylori-infected
astric epithelial cells. The inﬂammatory cytokine IL-8 and ROS
ncrease in the H. pylori-infected gastric mucosa. First, ACs inhibit
he phosphorylation of MAPKs, translocation of NF-B and IB
egradation. Secondly, they also inhibit H. pylori-induced iNOS and
OX-2 mRNA expression and IL-8 production [508]. Additionally,
n vitro studies showed that the anthocyanins inhibit the mRNA
nd/or protein expression levels of COX-2, NF-B and various inter-
eukins and exhibit antiinﬂammatory effects in multiple cell types
509,510].r Biology 35 (2015) S151–S184 S163
These studies suggest that anthocyanins signiﬁcantly inhibit
induced proinﬂammatory mediators, such as nitric oxide (NO) and
prostaglandin E2, as well as proinﬂammatory cytokines including
TNF- and IL-1, without signiﬁcant cytotoxicity. Anthocyanins
also downregulated excessive expression of inducible NO synthase,
COX-2, TNF-, and IL-1 in a dose-dependent manner in different
cancers. Moreover, anthocyanins inhibited nuclear translocation of
NF-B and IB degradation as well as phosphorylating MAPKs.
In addition to these antiinﬂammatory effects, anthocyanins
have been shown to inhibit the growth and invasion of SKHep-1
cells through reduced expression of MMP-9 and urokinase plas-
minogen activator (u-PA) [511]. Similarly, a MMP-9 and u-PA
mediated reduction of migration and invasion was  observed in
highly metastatic A549 human lung carcinoma cells through cyani-
din 3-rutinoside and cyanidin 3-glucoside (anthocyanins). This
inhibition was  also through the downregulation of activation of
c-Jun and NF-B [512]. Treatment with anthocyanins (such as
delphinidin, cyanidin, and pelargonidin) in normal human epi-
dermal keratinocytes inhibited UV-B-mediated degradation and
phosphorylation of IB and activation of IKK  ˛ which further
inhibited nuclear translocation and phosphorylation of NF-B/p65
at Ser (536) [513].
Some caution must be exercised, because anthocyanins are often
addressed as a homogenous class of agents, but they represent
a group of structurally dissimilar molecules. Some studies also
look at anthocyanidins (which are similar to anthocyanins but
without sugar moieties). Both anthocyanins and anthocyanidins
(especially cyanidin and delphinidin) have been subjected to exten-
sive mechanistic studies in relation to antiproliferation, induction
of apoptosis and inhibition of activities of oncogenic transcription
factors and protein tyrosine kinases. Water soluble anthocyanins
are mostly 3-glucosides of the anthocyanidins. The most common
anthocyanidins are pelargonidin, delphinidin, peonidin, petuni-
din, malvidin and cyanidin. Peonidin 3-glucoside and cyanidin
3-glucoside extracted from black rice (Oryza sativa ssp. indica)
inhibit the growth and invasion of SKHep-1 cells through reduced
expression of MMP-9 and urokinase plasminogen activator (u-PA)
[511]. Similarly, MMP-9 and u-PA mediated reduction of migra-
tion and invasion was observed in highly metastatic A549 human
lung carcinoma cells through cyanidin 3-rutinoside and cyanidin
3-glucoside (extracted from Morus alba). This inhibition was  also
through the downregulation of activation of c-Jun and NF-B [512].
Treatment with pomegranate-derived delphinidin, cyanidin,
and pelargonidin in normal human epidermal keratinocytes
inhibited UV-B-mediated degradation and phosphorylation of IB˛
and activation of IKK  ˛ which further inhibited nuclear translo-
cation and phosphorylation of NF-B/p65 at Ser [513]. Based
on the accumulating evidence, pure anthocyanidins as well as
berry extracts enriched with anthocyanidin showed higher chemo-
preventive activities than berry extracts with high anthocyanin.
The major points of concern are pH, temperature and light-
dependent interconversion of anthocyanins and anthocyanidins, a
greater susceptibility of anthocyanidins (in comparison to the gly-
cosides) to chemical decomposition, and shorter half-lives in the
biophase.
Notably, a number of immunosuppressive effects of berry
extract rich in anthocyanins have been reported by Hushmendy
et al. [514] who demonstrated that anthocyanidin rich fractions
inhibit T-cell proliferation and IL-2 production on anti-CD3 plus
anti-CD28-activated primary human T-lymphocytes in culture
[514]. However, very little research on anthocyanidins and the
immune system in cancer exists, suggesting that this is an area that
needs further investigation.
In general, these ﬁndings suggest that anthocyanins offer sub-
stantial chemopreventative and therapeutic potential, although
there is paucity of data regarding the bioavailability of anthocyanin.
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nly a small portion of orally ingested anthocyanins is absorbed
<1%). Maximum plasma levels are reached within 2 h of consump-
ion. About 68% of absorbed anthocyanins are metabolized, and
xcreted as monoglucuronides [515]. Low bioavailability of the
nthocyanins is due to their extensive metabolism in the tissues
nd by the colonic microﬂora. The gut microﬂora degrades antho-
yanins to release simple phenolics that conjugate in intestine and
ater in liver and hamper the absorption process. However, some
eports contradict this observation and suggest that anthocyanin
lycosides remain intact during absorption [516]. Although the
ioavailability of cyanidin-3-glucoside and anthocyanin as shown
hrough the above report is low, Mayrczylo et al. demonstrated
ystemic levels of parent cyanidin-3-glucoside and total antho-
yanins as 1.7% and 3.3% respectively in C57BL6J mice that received
yanidin-3-glucoside by oral gavage or tail vein injection [517].
Overall, in most in vitro and in vivo assays anthocyanins are not
enotoxic. Some evidence of genotoxicity was provided by a single
n vitro study using pure anthocyanidins. However, the genotoxicity
f grape seed extract was negative in a bone marrow micronucleus
est in vivo. Moreover, in guinea pigs and dogs, no short-term or
ubchronic toxic effects were observed at 3 g/kg anthocyanins and
5% of grape-skin extract respectively. In addition, in rats fed with
 g/day unspeciﬁed anthocyanins extract or grape seed extract no
oxic effect was observed. But because of a lack of data, no ﬁrm
onclusion can be drawn with respect to long-term toxicity or car-
inogenicity of anthocyanins [515].
.6. Genistein
Genistein (GEN) is a prominent isoﬂavone which inhibits cell
rowth and induces apoptosis in vitro and in vivo without tox-
city [518,519]. It inhibits activated AKT, the downstream target
f many pathways such as Notch [520], and IGF-1 in pancreatic
ancer cells [521], in osteosarcoma [522] and breast cancer [523].
dditionally, GEN inhibits the activity of AKT-targets like FOXM1
n pancreatic cancer cells [520] and FOXO3 [524] in colon cancer
ells. AKT also forms a complex with human TERT, heat shock pro-
ein 90, p70S6 kinase and mTOR and GEN restrains the formation of
his complex [525]. In pancreatic cancer cells GEN inhibits growth
ia inactivation of Notch-1/AKT/FOXM1 [520]. Estrogen receptor-
/AKT mediated inhibition was also observed in DLD-1 human
olon adenocarcinoma cells [526]. GEN also targets AKT and p21
AF1/CIP1 in BRCA1-mutant human breast cancer cell lines [527].
EN induced AKT-mediated enhanced apoptosis/down-regulation
f AKT has also been reported in combination with compounds like
rsenic trioxide in human hepatocellular carcinoma [528], geﬁtinib
n NSCLS [529], gemcitabine in human osteosarcoma [522,530], cis-
latin in cervical cancer cells [531], cetuximab in oral squamous
ell carcinoma [532], photoactivated hypericin in breast cancer
ells [533] and indole-3-carbinol in human colon cancer HT-29
ells [534]. GEN also inhibits the carcinogenic effect of 17 beta
stradiol or bisphenol-A via ER/IGF-1/AKT pathway in BG-1 ovar-
an cancer cells [535] and also downregulates FOXO3 activity in
olon cancer cells [524]. It also modulates MAPKs/AKT in cervical
ancer cells [536]. Repression of breast cancer stem cell-induced
ammospheres by GEN was similar to the AKT inhibitor perifosine
nd was related to enhanced tumor suppressor PTEN expressions
537]. Increased ceramide and lipid raft cholesterol accompanied
ith genistein inhibited the cell viability of prostate cancer cells via
he partial contribution of EGFR-AKT/p70S6k pathway and down-
egulation of androgen receptor [538,539].
Some reports also show a distinct genistein effect whereby
t induces PI3K/AKT nongenomic ER signaling to the histone
ethyltransferase enhancer of zeste homolog 2 (EZH2). As a result,
his phosphorylates and represses EZH2 and reduces levels of
3K27me3 repressive mark in chromatin during developmentalr Biology 35 (2015) S151–S184
reprogramming, and promotes uterine tumorigenesis [540]. In
colon cancer cells, membrane androgen receptors (mAR) activation
inhibits the prosurvival signals AKT/Bad in vitro and in vivo and
blocks migration of colon cancer cells via regulation of vinculin (a
protein controlling cell adhesion) signaling and actin reorganiza-
tion, supporting the powerful tumoristatic effect of mAR receptors.
GEN inhibited actin reorganization and restored the motility of
these cells and reversed the tumoristatic effect of mARs [541].
A number of concerns have been raised about the estrogen-
like effects of natural isoﬂavones (i.e., the possible promotion of
estrogen-sensitive cancers) [542–544]. However, a recent nested
case-control study and meta-analysis of numerous epidemiological
studies show an inverse correlation between GEN intake and breast
cancer risk and a number of other clinical studies support the breast
and uterine safety of puriﬁed naturally derived GEN administered
for up to 3 years [545].
Most phase I and phase II clinical trials of GEN have consid-
ered normal dietary dose ranges, i.e.,  0.3–1 mg/kg body weight/day
[546]. In one study patients were treated with 2 mg  GEN/kg
body weight and compared against no treatment prior to under-
going radical prostatectomy for localized prostate cancer [547].
After treatment, it was  shown that GEN decreased MMP-2 gene
expression to 24% of the level seen in control subjects (blood
concentrations of free GEN were approximately 140 nM in the GEN-
treated cohorts while control group levels were below detection)
[547]. Messing et al. initiated a phase 2 randomized, placebo-
controlled trial with oral GEN (300 or 600 mg/d) as the puriﬁed soy
extract G-2535 and found that GEN was more effective at lower
dose on bladder cancer tissue through EGFR phosphorylation but
the AKT pathway was  unaltered in both in vivo conditions [548].
Another phase II clinical trial with GEN administered at a dose
of 531 mg  twice daily P.O. starting day −7 until the end of study
participation with erlotinib, and gemcitabine in advanced pancre-
atic cancer did not appear to increase the survival of patients with
advanced pancreatic cancer [549]. In another phase II trial, sub-
jects with progressive prostate cancer were treated with soy milk
three times daily for 12 months (approx. 1 mg GEN/kg/day) which
decreased the rate of increase of serum prostate-speciﬁc antigen
(PSA) when compared to that which was  seen in subjects prior to
entering the study [550]. Finally, a third phase II study of GEN in
men  with various stages of prostate cancer used soy extract (6 mg
GEN/kg/day for 6 months) [551] with 17% of the participants expe-
riencing a decrease in their PSA levels.
From an immune perspective, a range of effects have been
found. For example, Yellayi et al. reported that sub-cutaneous
GEN injections (8 mg/kg/day) in ovariectomized adult mice lead to
estrogen receptor (ER) and non-ER-mediated inhibition of thymo-
cyte and CD4(+)CD8(−) helper T cell lineage maturation as well as
systemic lymphocytopenia [514]. Additionally, GEN produced sup-
pression of humoral immunity. The signiﬁcant thymic and immune
changes in mice produced by serum GEN levels at 8 mg/kg/day
was also comparable to those reported in soy-fed human infants
[514]. GEN also appears to compete with endogenous 17beta-
estradiol for estrogen receptors to suppresses Ag-speciﬁc immune
responses. Speciﬁcally 20 mg/kg GEN downregulated OVA-speciﬁc
proliferative responses, interferon-gamma production levels and
immunoglobulin (Ig)G1 without reduction in responses to anti-CD3
monoclonal (m)antibody and Ag-presenting activity of CD11c(+)
dendritic cells [552]. And GEN has also been shown to potently
induce the granzyme B inhibitor, proteinase inhibitor 9 (PI-9) in
MCF-7 human breast cancer cells inhibiting the ability of human
NK cells to lyse breast cancer cells [553].By contrast, however, the ingestion of GEN signiﬁcantly
increased lymphocyte proliferation and LDH release, and caused
a signiﬁcant increment in IFN- in a mouse model of human
papillomavirus associated-cervical cancer resulting in a signiﬁcant
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herapeutic effect (compared to a control group) [554]. GEN also
roduced a signiﬁcant increase in ex vivo cytotoxic T lympho-
yte (CTL), a potentiating effect on NK cells (but a decrease in
he percentage of CD4(+)CD25(+) T cells), an increase in the pro-
uction of IFN-, and the activation of STAT1 and STAT4 in a
,12-dimethylbenz[a]anthracene (DMBA)-induced tumor model in
ice. This resulted in an antitumor effect and an enhancement
o host resistance in this study [555]. So the immunomodulatory
otential of GEN appears to be quite nuanced and it may  require
urther investigation before we fully understand how these effects
mpact various cancers.
. MicroRNA (MiR)
In this section we also review the known impact of these
pproaches on microRNA (miRs), a relatively new area of intense
nterest in cancer research. miRs are small non-coding RNAs that
egulate gene expression (post-transcriptionally) and target about
0% of the protein-coding mRNAs [556,557]. They are master reg-
lators of multiple cellular pathways, and the deregulation of
iRNAs plays a fundamental role in the onset and progression of
any cancers [556].
The miRBase database (http://www.mirbase.org) is a searchable
atabase of published miRNA sequences and annotation. miRBase
ersion 16.0 has 1048 miRNA sequences annotated in the human
enome, and miRs and a single miR  can target approximately 200
ranscripts simultaneously. Each miR  can target hundreds of mes-
enger RNAs (mRNA)s and a single mRNA is often the target of
ultiple miRs within a given cell type [557]. Many housekeeping
enes have evolved with shorter length of 3′-UTR to avoid miR  reg-
lation [558]. About 50% of annotated human miR  genes are located
n cancer associated genomic regions or fragile sites that are sus-
eptible to ampliﬁcation, deletion and translocation in a variety
f tumors [23,559]. Because of this, some miRs could act as either
umor suppressors or oncogenes (oncomir) [560–564].
The posttranscriptional ﬁne tuning of mRNA and proteins levels
y miR  also plays an important role in developmental and immune
egulatory processes [565–569]. They are involved in the regulation
f nearly all aspects of cellular function including innate and adap-
ive immune responses [570–573]. Deregulated miR  expression
as been found in several autoimmune disorders and inﬂamma-
ory conditions [574–576]. Importantly, miRs have been found to
e either upregulated or downregulated in tumors [577–580]. Epi-
emiological studies suggests about 25% of all cancer may  be due to
hronic inﬂammation [3,8], and several miRs have been implicated
n both inﬂammation and cancer [569,581–584].
.1. MicroRNA-155
miR-155 is found on chromosome 21 (human) and 16 (mice)
585,586], and is generally considered to be an oncomir with
ostly proinﬂammatory effects. This miR  is upregulated by NF-B
566,587,588], which is pivotal in inﬂammation and cancer [589].
iR-155 is upregulated/activated in B and T cells, macrophages
nd dendritic cells [566,585,590,591]. miR-155−/− mice are highly
esistant to experimental autoimmune encephalomyelitis (EAE)
592,593]. Mechanistically, this appears to be due to the role of
iR-155 in mediating the production of IL-17 (Th17) and IFN-
Th1) producing CD4+ T cells [592].
miR-155 has been found at high levels in human B cell
ymphomas and other tumors [585,590,594–596]. Enforced over-
xpression of miR-155 in mouse B cells is sufﬁcient to trigger
urine B cell lymphoma [597]. It has also been reported that
iR-155 acts as an oncogene by targeting tumor suppressor gene
uppressors of cytokine signaling 1 (SOCS1) in breast cancer cellsr Biology 35 (2015) S151–S184 S165
[598]. Additionally, the upregulation of miR-155 by mutant p53
was reported to drive breast cancer invasion [599] and this miR
suppressed the expression of tumor protein p53 induced nuclear
protein 1 (TP53INP1) [600]. miR-155 may  also play a role in mul-
tiple sclerosis (MS) and rheumatoid arthritis (RA), where elevated
levels have been found in brain lesions of MS  patients [601] and in
synovial samples of RA patients [602]. Overall, miR-155 is emerg-
ing, then, as a key oncomir linking inﬂammation and cancer.
4.2. MicroRNA-146
miR-146 is a miRNA family, consisting of two evolutionarily
conserved miRNA genes: miR-146a and miR-146b. miR-146 sup-
presses inﬂammation and cancer. The distal region of chromosome
5q, which contains miR-146a gene (5q33) in humans is reported
to harbor susceptibility loci for autoimmune diseases such as RA
[603], Crohn’s Disease [604], asthma [605] and psoriasis [606]. miR-
146a and miR-146b, when expressed in highly metastatic human
breast cancer cells, function to negatively regulate NF-B activity
[607]. miR-146a and miR-146b have also been found to be highly
expressed in RA synovial tissue [608]. Although RA is not a high
cancer risk disease, other auto-immune, chronic inﬂammatory dis-
eases such as inﬂammatory bowel disease (IBD) are treated in a
similar manner (e.g., TNF inhibitors). Therefore, it would be inter-
esting to examine the role of this miR  in such diseases. miR-146a
also directly targets PGE2 synthase and increased expression of
miR-146a in bone mesenchymal stem cells (BMSCs) is correlated
with the inhibition of PGE2 synthase-2 (Ptges-2) and the inhi-
bition of PGE2 release [609]. In contrast to miR-155, miR-146a
limits T cell activation and promotes resolution of inﬂammatory
responses [610]. miR-146a−/− mice develop spontaneous autoim-
munity and myeloid cancers upon aging, due to hyperactivation
of T cells via de-repression of the proinﬂammatory proteins, IL-1
receptor-associated kinase 1 (IRAK1) and TNF receptor associated
factor (TRAF)6 [610–612]. Finally, Xie et al. recently reported that
the inhibition of miR-146 results in increased IL-1, IL-6 and TNF-
 secretion, as well as increased expression of IRAK1 [613]. Such
studies, then, again highlight a key role of miR-146 in inﬂammation
and cancer.
4.3. MicroRNA-21
miR-21 is an oncomir. Its oncogenic activity has been reported
where it targets and represses important tumor suppressor genes
such as PTEN [614], programmed cell death 4 (PDCD4) [615],
tropomyosin 1 (TMP1) [616], B-cell translocation gene 2 (BTG)
[617], components of the p53 pathway [618] and also modu-
lates growth inhibitory and pro-apoptotic cytokine TGF- signaling
[618] to further enhance its tumorigenic effects. miR-21 dere-
gulation is a very early event in the multistep progression of
pancreatic ductal adenocarcinoma (PDAC) [619]. miR-21 expres-
sion is increased in breast and colorectal cancer and in the
serum of patients with hepatocellular carcinoma (HCC) [620,621].
With regards to its role in inﬂammation, miR-21 expression has
been shown to be induced in macrophages and peripheral blood
mononuclear (PBM) cells upon LPS challenge [622] and in mam-
mary epithelial cells by inﬂammatory signals [582]. Similarly
induction of miR-21 by IL-6 is a STAT3 dependent mechanism that
is responsible for the survival of multiple myeloma cells [623]. It
appears that STAT3 together with miR-21, miR-181b-1, PTEN and
cylindromatosis (CYLD) is a part of the epigenetic switch that links
inﬂammation to cancer in several cancer types including breast,
colon, prostrate, lung and HCC [581]. Finally, Schetter et al. have
reported a positive correlation of IL-6 with miR-21 expression in
human colon cancer tissues [624], further supporting the role of
miR-21 in linking inﬂammation and cancer.
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.4. MicroRNA-17–92 Cluster
miR-17–92 (OncomiR-1) [562] is a cluster of miRs located on
uman chromosome 13 and encodes a polycistronic miR  gene
or six mature functional miRs: miR-17, miR-18a, miR-19a, -
0, -19b and -92 [625]. Overall, this cluster of miRs has cancer
nd inﬂammation-promoting properties. For example, SOCS1, a
ene frequently silenced in multiple myeloma, and a strong anti-
nﬂammatory instigator, is targeted by miR-19, elucidating the
roinﬂammatory property of miR-19 and its possible link to tumor-
genesis [626,627]. miR-17–92 clusters weaken TGF- signaling by
unctioning both upstream and downstream of phospho-SMAD2 as
ell as through direct inhibition of TGF- responsive genes [628].
iR-19b positively regulates NF- signaling for proinﬂammatory
ytokine production, is involved in controlling several negative
egulators of NF-B signaling, and plays a crucial role in the pathol-
gy of autoimmune diseases [629]. Additionally, miR-17–92 is
 well-established player of oncogenesis and overexpression of
his cluster and in a Myc-driven mouse model of B-cell leukemia
ccelerates tumor development [562]. miR-19 can exert its onco-
enic effect through its repression of tumor suppressors PTEN and
rotein phosphatase 2 (PP2A), pro-apoptotic molecule B-cell lym-
homa 2 interacting mediator of cell death and Protein kinase,
MP-activated, alpha 1 catalytic subunit [630–632]. Overall, the
iR-17–92 cluster, based on its role in inﬂammation and cancer
ould also serve as a potential therapeutic target.
.5. MicroRNA-196
miR-196 is considered an oncomir, is upregulated in several
ancer types [569] and is associated with Barrett’s esophagus-
o-adenocarcinoma disease progression [633]. Luthra et al.
emonstrated miR-196a directly targets the antiinﬂammatory
layer, annexin 1 and has growth promoting and antiapoptotic
roperties in esophageal adenocarcinoma cell lines [634]. miR-196
s overexpressed in inﬂamed intestinal epithelial of Crohn’s dis-
ase patients and downregulates immunity-related GTPase family
 protein (IRGM) protective variant (c.313C) but not the risk associ-
ted allele (c.313T) [635]. Also, the Rs11614913 SNP in miR-196a-2
ay  promote susceptibility to breast and lung cancer [636]. These
ncogenic and proinﬂammatory properties of miR-196a support its
ole in inﬂammation and cancer.
.6. microRNA-663
miR-663 is currently reported as an antiinﬂammatory and
umor suppressor miR  and impairs the upregulation of miR-
55 by inﬂammatory stimuli [637,638]. The overexpression of
ypomethylated miR-663 induces chemotherapy resistance in
uman breast cancer cells by targeting heparan sulfate proteogly-
an 2 (HSPG2) [639].
.7. Other microRNAs involved in inﬂammation and cancer
miR-9 is canonically induced by NF- following TLR4 activa-
ion in human neutrophils and monocytes and provides feedback
o repress NF-B signaling through direct targeting of p50 mRNA
640]. Overexpression of miR-9 by MYC/MYCN is involved in can-
er metastasis [641,642]. This elucidates a possible link between
nﬂammation and cancer by miR-9. Several studies reported
pregulation of miR-210 in hypoxic condition [643–645] and its
mportance for cell survival [646]. miR-210 is a sensor for hypoxic
tress during tumorigenesis, where increased miR-210 expres-
ion inhibits tumor growth to provide tumor cells an opportunity
o prevail in stressful hypoxic condition [647]. Thus, a possible
onnection between hypoxia and tumorigenesis is mediated by
iR-210. miRNA-16 is a putative tumor suppressor miR, and isr Biology 35 (2015) S151–S184
downregulated in a variety of human cancers [648–654]. One rec-
ognized function of miR-16 is that it controls the cell cycle primarily
through a G1 cell cycle checkpoint [649,655–662].
The ﬁnding that miR-16 is upregulated in high risk colon cancer,
and chronic inﬂammatory disease possibly indicates an adaptive
upregulation of this tumor suppressor miR  in response to inﬂam-
matory stress. Finally, inhibiting the peptidyl arginine deiminase
(PAD) enzyme, which catalyzes the post-translational conversion
of peptidyl-arginine to peptidyl-citrulline (“citrullination”) causes
an increase in miR-16 [663]. The fact that citrullination is thought to
be an inﬂammation-dependent process [664] supports the notion
that miR-16 is involved in the suppression of inﬂammation. miR-
125b expression is decreased after LPS challenge in macrophage
cells [665], and additionally in several inﬂammatory condition such
as psoriasis and atopic eczema [666]. Further down-regulation of
miR-125b has been reported in several tumor types such as thyroid
anaplastic carcinomas, hepatocarcinomas, oral, bladder cancer,
ovarian and breast cancer [569]. Finally, miR-663 is currently
reported as antiinﬂammatory and tumor suppressor microRNA
and impairs the upregulation of miR-155 by inﬂammatory stimuli
[637,638].
4.8. Selected approaches that modulate miR involved in
inﬂammation and cancer
Signaling pathways involving inﬂammation and cancer are
clearly regulated by miRs so here we speciﬁcally discuss studies
that relate to the therapeutic approaches reviewed above. For ref-
erence sake, additional details on other dietary components that
regulate miRs have been reviewed in detail elsewhere [557,667].
4.9. Resveratrol
Since both resveratrol and miR  inﬂuence cellular homeostasis
and disease conditions, resveratrol could act through miRs in mod-
ulating and targeting the factors involved in disease and cellular
homeostasis. Tili and Michaille reviewed resveratrol, miRs, inﬂam-
mation and cancer [668], and note that resveratrol has been shown
to induce the expression of miR-663, a tumor-suppressor and
antiinﬂammatory miR, while down-regulating proinﬂammatory
miR-155 and oncogenic miR-21.
4.10. Curcumin
Curcumin regulates the expression of genes that are involved in
the regulation of cellular inﬂammatory and cancer signaling path-
ways, such as NF-B, AKT, MAPK and other pathways [669,670].
These signaling pathways are in turn regulated by several miRs. In
a spontaneously arising retinal pigment epithelia cell line (ARPE-
19 cells), curcumin treatment lowers the expression of miR-17–92
cluster and its pre-treatment attenuates H2O2 induced expres-
sion of miR-15b, miR-21, miR-17, miR-196b and miR-9 [671]. The
curcumin analog CDF decreases pancreatic cancer cell survival by
increasing the expression of the tumor suppressor miRs, Let-7 and
miR-146a, which are typically lost in pancreatic cancer [672]. The
mesenchymal phenotype of gemcitabine-resistant pancreatic can-
cer cells has been shown to be reversed by simply treating the cells
with either CDF or curcumin which upregulates the expression
of miR-200b and miR-200c [673]. Curcumin also reduces miR-21
expression and activity via AP-1, suppresses tumor progression,
and stabilizes the tumor suppressor Pdcd4 in colorectal cancer cells
[674].4.11. Genistein
Genistein enhances the apoptotic effects of exogenous miR-16
in murine CLL cells [675]. Isoﬂavones regulate miR function by
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nducing expression of miR-200 and let-7 to reverse EMT  phe-
otype [676]. Isoﬂavones have also been shown to upregulate
iR-146a and target EGFR and IRAK-1/NF-B signaling to inhibit
ancreatic cancer cell invasion [677]. These studies provide evi-
ence that isoﬂavones regulate miRs involved in inﬂammation and
ancer which may  provide a prevention and/or treatment measure.
.12. EGCG
EGCG is a major catechin in green tea and has been implicated
n many pathways involved in inﬂammation and cancer. EGCG
pregulates miR-210 in human and mouse lung cancer cells in
ulture which leads to reduced cell proliferation mediated by sta-
ilization of HIF-1  [678]. EGCG antagonizes androgen action and
own-regulates miR-21 and upregulates tumor suppressor miR-
30 in prostate tumors of mice [679]. EGCG has also been shown to
ecrease expression of oncomirs (miR-92, miR-93, and miR-106b)
nd increase the expression of tumor suppressor miRs (miR-7-1,
iR-34a, and miR-99a) in neuroblastoma cells [680].
. Cross-validation for tumor promoting inﬂammation
Given that the heterogeneity that is present in most cancers,
t is our assumption that the complete arrest of the various sub-
opulations of immortalized cells in any given cancer will require
imultaneous actions on mechanisms that are important for several
spects of cancer’s biology. We  therefore believe that it is impor-
ant to be able to anticipate synergies that might be achieved by
cting on speciﬁc targets and with speciﬁc approaches (i.e., when
ontemplating an approach aimed at a broad-spectrum of targets).
ccordingly, in this review the prioritized target sites and the
pproaches that have been identiﬁed (as potential ways to reach
hose targets) were all cross-validated by conducting a background
iterature research. A team of researchers consisting of specialists
n each area speciﬁcally sought to determine the relevance of these
argets and the nominated approaches across a number of impor-
ant areas of cancer’s biology.
In this regard, targets and approaches that were not only rel-
vant for this area of study, but also relevant for other aspects of
able 1
ross validation of targets – prioritized targets evaluated for known effects in other cance
Potential targets for inﬂammationa
Other hallmarks
Inhibit Cox-2 Inhibit NF-B Block MI
Genomic Instability +
[681]
+
[682]
0 
Sustained proliferative signaling +
[686–688]
+
[689–691]
+
[54,692]
Evasion of anti-growth signaling +
[698,699]
0 +
[53,700]
Resistance to apoptosis +
[706]
+
[707]
+
[708]
Replicative immortality +
[713–715]
+/-
[716–718]
+
[719,720
Deregulated metabolism +
[724]
+
[725–727]
0 
Immune system evasion +
[737,738]
+
[739]
+
[740]
Angiogenesis −
[743]
±
[744,745]
+
[54,55,74
Tissue invasion and metastasis +
[750–753]
+
[754]
+
[755,756
Tumor microenvironment +
[761]
+
[762]
+
[763]
a Targets that were found to have complementary, anticarcinogenic actions reported 
o  have procarcinogenic actions in another hallmark area were indicated with “−”. In ins
eports showing both anticarcinogenic potential and procarcinogenic potential), the sym
ocument the relevance of a target in a particular aspect of cancer’s biology, we docume
olumns  of the table. The number of anticarcinogenic, procarcinogenic and mixed cross-
ast  three columns of the table.r Biology 35 (2015) S151–S184 S167
cancer’s biology (i.e., anticarcinogenic) were noted as having “com-
plementary” effects. Those that were found to have procarcinogenic
actions were noted as having “contrary” effects. In instances where
reports on relevant actions in other aspects of cancer biology
were mixed (i.e., reports showing both procarcinogenic potential
and anticarcinogenic potential), the term “controversial” was used.
Finally, in instances where no literature support was found to doc-
ument the relevance of a target site or approach in a particular
aspect of cancer’s biology, we  documented this as “no known rela-
tionship”. These validation results are shown below in tabular form
in Tables 1 and 2.
The decision to review priority target sites and approaches for
reports of cross-hallmark effects was  driven by the fact that many
individual studies and reviews fail to account systematically for the
spectrum of incidental actions that can result from various forms
of therapeutic interventions. It is our belief that this approach con-
stitutes a better way to ensure that we had assembled a reasonably
thorough review of the literature (i.e., where any sort of evidence
of cross-hallmark activity had been reported).
Because future research on therapeutic combinations will likely
involve empirical testing of mixtures of constituents, we wanted
to create a starting point for other researchers who might be
considering translational projects. We  anticipated interest in
approaches reported to exhibit a large number of anticarcinogenic
actions across the hallmarks and we anticipated that a lack of pro-
carcinogenic potential was  important to identify (since targets or
approaches that have been shown to exert procarcinogenic actions
would potentially represent a confounding and unwanted inﬂu-
ence/factor in empirical research). A summary of these reports is
also provided in Tables 1 and 2.
Note that, in some instances, the underlying evidence used to
support the indication of a cross-hallmark relationship was robust,
consisting of multiple studies involving detailed in vitro and in
vivo ﬁndings. In other instances, however, the underlying evi-
dence that was  used to report the existence of a cross-hallmark
relationship was quite weak (e.g., consisting of only a single in vitro
study involving a single cell-type). Additionally, there are examples
of approaches that are known to exert different effects at different
dose levels and in different tissues but dose-levels and cell/tissue
r hallmark areas.
F  Block TNF Block iNOS Block AKT Inhibit CXC
chemokines
0 0 +
[683–685]
0
+
[693,694]
+
[695]
+
[696]
+
[697]
+
[701,702]
+
[703]
+
[704]
+
[705]
+
[709]
+
[710]
+
[711]
+
[712]
]
+
[721]
0 +
[711,722,723]
0
+
[728–731]
+
[732,733]
+
[234,734–736]
0
−
[44]
0 +
[741]
±
[742]
6]
±
[154]
−
[747]
+
[748]
±
[749]
]
+
[757]
+
[758]
+
[759]
+
[760]
+
[764]
±
[765]
+
[766,767]
±
[768,769]
in another hallmark area were indicated with “ + ”, while targets that were found
tances where reports on relevant actions in other hallmark areas were mixed (i.e.,
bol “±” was used. Finally, in instances where no literature support was found to
nted this as “0”. These cross-hallmark relationships are reported in the ﬁrst eleven
hallmark relationships for each target have been summed and are reported in the
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Table 2
Cross validation of approaches. Selected approaches evaluated for reported actions in other cancer hallmark areas.
Approacha
Other hallmarks
Curcumin Resveratrol EGCG Lycopene Anthocyanins Genistein
Genomic instability +
[770]
+
[682]
+
[771]
+
[772]
+
[770]
+
[773]
Sustained proliferative
signaling
+
[774]
+
[775–777]
+
[678,778]
+
[488,779]
+
[780,781]
±
[782,783]
Evasion of anti-growth
signaling
+
[784,785]
+
[786,787]
+
[788,789]
+
[790–792]
+
[793]
±
[544,794,795]
Resistance to apoptosis +
[796]
+
[797]
+
[798]
+
[799]
+
[800]
+
[518]
Replicative
immortality
+
[774,801,802]
+
[803,804]
+
[805,806]
0 +
[807]
+
[808,809]
Deregulated
metabolism
+
[810]
+
[811,812]
+
[813–815]
0 0 ±
[816]
Immune system
evasion
+
[371]
±
[425,817–819]
+
[820]
0 0 ±
[554,821]
Angiogenesis +
[822]
±
[823]
+
[824]
+
[825]
+
[826]
+
[827]
Tissue invasion and
metastasis
+
[774,828]
+
[829]
+
[312,830,831]
+
[832]
+
[833]
+
[830]
Tumor
microenvironment
+
[834,835]
+
[836,837]
+
[820,838]
+
[772,839]
+
[840]
+
[841]
a Approaches that were found to have complementary, anticarcinogenic actions in a particular hallmark area were were indicated with “ + ”, while approaches that were
found  to have procarcinogenic actions in a particular hallmark area were indicated with “−”. In instances where reports on relevant actions in other hallmarks were mixed
(i.e.,  reports showing both anticarcinogenic and procarcinogenic potential), the symbol “±”  was  used. Finally, in instances where no literature support was found to document
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f  the table. Finally, the number of anticarcinogenic, procarcinogenic and mixed cro
hree  columns of the table.
ypes were not used to discriminate when gathering together these
eported actions.
Nonetheless, given that the overarching goal in this project was
o create a foundation that would allow researchers to look system-
tically across the literature in each of these areas, the tables should
erve as a useful starting point as long as they are approached with
aveats in mind and a degree of caution. Essentially, we  believe
hat this heuristic model should be useful to consider synergies
hat might be anticipated in testing that involves certain targets
nd/or mixtures of chemical constituents that are being considered
or therapeutic effects.
. Summary/conclusions
In sum, it was our goal to explore a series of high priority anti-
nﬂammatory targets for therapeutic intervention in cancer as part
f a larger effort to develop a broad-spectrum approach aimed
t a wide range of targets that are relevant for cancer biology.
he selected targets MIF, COX-2, NF-B, TNF-, iNOS, AKT and
XC chemokines represent a promising and interrelated set of tar-
ets that are pleiotropic, with demonstrated potential not only for
nﬂammation, but also for a wide range of other effects that support
he various hallmark phenotypes found in a wide range of cancer
ypes.
At the same time, the approaches that we selected to act on
hose targets (curcumin, resveratrol, EGCG, genistein, lycopene,
nd anthocyanins) are all agents than have demonstrated a range
f anticancer effects. While we focused mainly on antiinﬂamma-
ory effects, many of these approaches have demonstrated a range
f anticarcinogenic actions as well. In addition to the most widely
eported direct effects of these agents, we have also summarized
iR  regulated gene expression related to inﬂammation and cancer,
nd the known effects of these approaches on these MiRs.
Given the tight coupling between inﬂammation and the immune
ystem, we also wanted to consider the possibility that proposed
ctions on important antiinﬂammatory targets, and/or the chronic
dministration of the antiinﬂammatory chemicals might predis-
ose individuals to infection or modulate the immune system in
 manner that might be relevant for immune-related antitumor as “0”. Threse cross-hallmark relationships are reported in the ﬁrst eleven columns
llmark relationships for each target have been summed and are reported in the last
effects. Perhaps not surprisingly, an increased risk of infection
appears to be a concern for therapeutic approaches aimed at sup-
pressing MIF, Cox-2, NF-B, and TNF-, and in the use of curcumin
(as a therapeutic approach). By contrast, EGCG appears to have a
protective effect against bacterial infection. Immunomodulation of
antitumoral effects is also a nuanced picture. COX-2 inhibition and
PI3K-AKT pathway inhibition both appear to be attractive targeting
strategies that have antitumoral effects that are immune-related.
Similarly, curcumin, resveratrol and EGCG have also been shown
to act on the immune system in a favorable manner. However,
lycopene and genistein have demonstrated a range of competing
effects on the immune system making their utility from this per-
spective more difﬁcult to discern.
Future research should address the ambiguities posed by the
wide range of CXC Chemokines and their various effects, as precise
targets are needed to better characterize the range of effects and
synergies that might be anticipated. Similarly, within the selected
approaches, speciﬁc anthocyanins that appear to have the great-
est promise should be isolated and better characterized for effects
across the range of cancer hallmark phenotypes, and for bioavail-
ability and toxicity.
Ideally, future translational work would utilize the agents that
we have identiﬁed in this review combined as constituents within a
multi-pronged antiinﬂammatory approach with very little/no tox-
icity.
However, any multipronged strategy that focuses on these tar-
gets and/or approaches will need to carefully consider the potential
for increased risks related to infection and anticipate the possibil-
ity for a range of immunomodulation that will have relevance for
antitumoral effects.
Bioavailability challenges with a number of these agents are
starting to be addressed, and foreseeably recent advances that uses
implantable polymeric micelles, liposomes, microspheres, nano-
delivery systems, phospholipid-based delivery systems and other
systems (c.f. [359–362]) will help address this issue.The cross-validation tables (Tables 1 and 2) are offered here as
a simple heuristic framework that is intended to help researchers
approach the topic of anticipated synergies. Although these initial
results do not represent a homogenous set of underlying data, it
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s hoped that they can serve as a starting point for the transla-
ional research that will be needed. Rigorous experimentation will
bviously be needed to determine whether or not actual synergies
merge that can be predicted using this approach. Other syner-
ies may  emerge depending on the speciﬁc constituents and model
sed.
The key is to recognize that a low-toxicity approach aimed at
any important targets to reduce tumor-promoting inﬂammation
s only a stepping stone. Most cancers harbor signiﬁcant genetic
eterogeneity [4], and patterns of relapse following many ther-
pies are due to evolved resistance to treatment. Consequently,
n antiinﬂammatory approach along these lines should be devel-
ped and then combined with other similar approaches that aim
o target the many disease-speciﬁc pathways that have relevance
cross the range of hallmark phenotypes. A much broader range
f targets overall may  be the only chance we will have to address
his heterogeneity. It is a promising approach, but a considerable
mount of encompassing research needs to follow to determine
ethodological validity.
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